USE OF DOCOSAHEXANOIC ACID AND ARACHIDONIC ACID ENHANCING THE GROWTH OF PRETERM INFANTS

Abstract: A method for enhancing the growth of preterm infants involving the administration of certain long chain polyunsaturated fatty acids. It is preferred that the infants are administered an infant formula containing a combination of docohexaenoic acid and arachidonic acid.

Description: USE OF DOCOSAHEXANOIC ACID AND ARACHIDONIC ACID ENHANCING THE GROWTH OF PRETERM INFANTS Field of Invention The present invention concerns enhancing the growth of preterm infants involving administration of infant formula containing a combination of docosahexaenoic and arachidonic acid. Background of the Invention The long chain polyunsaturated fatty acids (LC PUFA) have been shown to be important in infant development. Particularly, arachidonic acid (ARA) and docosahexaenoic acid (DHA) are LC PUFA that are of special interest in infant nutrition because they are found in high concentrations in the brain (Sastry PS, Lipids of nervous tissue: composition and metabolism. Progress Lipid Res 1985;24:69-176) and the retina (Fliesler SJ and Anderson RE. Chemistry and metabolism of lipids in the vertebrate retina. Progress Lipid Res 1983;22:79-131). ARA (20:4n-6) and DHA (22:6n-3) are derived from the parent essential fatty acids linoleic acid (18:2n-6) and α-linolenic acid (18:3n-3) through alternate desaturation and elongation and accumulate rapidly in fetal neural tissue during the last months of gestation and the first months of postnatal life (Makrides M, Neuman MA, Byard RW, Simmer K, Gibson RA. Fatty composition of the brain, retina and erythrocytes in breast- and formula-fed infants. Am J Clin Nutr 1994;60:189-94). Unlike term infants, preterm infants do not fully benefit from the maternal and placental LC PUFA supply during the last trimester of pregnancy. Even though preterm infants are capable of synthesizing both DHA and ARA from their 18 carbon precursors (Carnielli NP, Wattimena DJL, Luijendijk IHT, Boerlage A, Degenhart HJ, Sauer PJJ. The very low birth weight premature infant is capable of synthesizing arachidonic and docosahexaenoic acids from linoleic and linolenic acids. Pediat Res 1996;40:169-174), it remains unclear whether the rate of synthesis is adequate to meet the optimal needs for central nervous system accretion in the absence of a dietary supply of these fatty acids. Preterm infants are dependent on their own dietary supply of linoleic and α-linolenic acids through either human milk, which also contains small but significant amounts of ARA and DHA or through commercially available artificial formulas, none of which in the United States contain ARA and DHA. It has been demonstrated in recent studies (Hoffman DR and Uauy R. Essentiality of dietary ω-3 fatty acids for premature infants: Plasma and red blood cell fatty acid composition. Lipids 1992;27:886-95) that the fatty acid composition of red blood cell membrane lipids in infants receiving formulas supplemented with DHA (0.35% of total fatty acids) was similar to human milk- fed infants. In the same study, Birch (Birch DG, Birch EE, Hoffman DR, Uauy RD. Retinal development in very-low-birth-weight infants fed diets differing in Omega-3 fatty acids. Investigation Ophthalmology Visual Science 1992;33:2365-76) found that retinal function improved with the provision of a dietary supply of DHA in very low birth weight infants. The first year growth of preterm infants fed standard formula compared to marine oil LC PUFA supplemented formula was studied by Carlson et al. (Carlson SE, Cooke, RJ, Werkman SH, Tolley EA. First year growth of preterm infants fed standard compared to marine oil n-3 supplemented formula. Lipids 1992:27:901-907). The experimental formulas provided 0.2% of total fatty acids as DHA and also provided 0.3% as EPA (20:5n-3). This EPA concentration is higher than found in human milk while the DHA level is similar to human milk. Beginning at 40 weeks from conception, marine oil supplemented infants compared to controls had significantly lower weight, length, and head circumference. From this study, Carlson (Carlson SE, Werkman SH, Peeles JM, Cooke RJ, Tolley EA. Arachidonic acid status correlates with first year growth in preterm infants. Proc Natl Acad Sci USA 1993;90:1073-77) hypothesized that dietary ARA could improve first year growth of preterm infants, in the context of restoring growth to the level of control formula containing no LC PUFA. In another study (Montalto, FB, et al., Pediatric Research, Vol 39, page 316A, abstract no. 1878) it was shown that male infants fed marine oil supplemented formula (containing DHA but essentially no ARA) had, by 4 to 6 months, lower head circumference, length, weight and fat free mass than standard formula fed infants. A third study also showed decreased weight at 9 and 12 months corrected age in preterm infants fed marine oil supplemented formula (with LC PUFA) to 2 months corrected age compared with control formula containing no LC PUFA (Carlson SE, et al., Am. J. Clin. Nutr., 63 pp 687-97, 1996). The prior art has demonstrated that infants with altered tissue LC PUFA levels, resulting from a lack of LC PUFA in their diets, may be at risk for neurological problems, may also have reduced scores on cognitive tests, and may have lower retinal development than human milk-fed infants. Worldwide regulatory organizations such as the WHO/FAO Expert Committee on Fats and Oils in Human Nutrition have recommended that LC PUFA be included in preterm infant formula. These recommendations have been made despite the negative effects observed of DHA supplements on growth. There has been no demonstration in the literature that ARA and DHA, particularly when added to infant formula, enhances the growth of infants above that demonstrated by control formulas not containing ARA and DHA. Summary of the Invention It has unexpectedly been discovered that preterm infants receiving infant formula supplemented with both DHA and ARA demonstrate enhanced growth. The present invention is directed to enhancing the growth of preterm infants comprising administering to said infants a growth enhancing amount ofDHA and ARA. Detailed Description of the Invention As reported in a review of preterm infant growth by Carlson, SE, (The Jrnl of Pediatrics, vol 125, pp 533-8, 1994) "After adjusting for postconceptional age, preterm infants show a decline (rather than a catch-up) in the normalized weight from approximately 2 to 4 months past expected term." Several prior art studies have documented the value of administering DHA to infants. However, when DHA, either as the primary LC PUFA or combined with EPA, is administered to preterm infants, said infants suffer from decreased growth. It has been suggested that ARA may be beneficial to growth; however, heretofore the growth effects of administering both DHA and ARA to preterm infants have been unknown. It has been surprisingly discovered that administering the combination of ARA and DHA results in enhanced growth of infants relative to infants fed DHA alone. It has also been discovered that preterm infants administered an infant formula containing ARA and DHA exhibit enhanced growth relative to preterm infants fed control formula without DHA and ARA, such as those formulas currently used in modem nurseries. It has further been discovered that practice of the method of the invention results in growth of preterm infants catching up in an unexpected short time to a reference group of normal term breast fed infants. The time to achieve growth similar or equivalent to normal term breast fed infants by practice of the method of the invention is less than 9 months corrected age; preferably less than 6 months corrected age, more preferably less than 4 months corrected age, even more preferably less than 2 months corrected age, and most preferably no greater than term corrected age. The method of the invention requires a combination of DHA and ARA. The weight ratio weight of ARA:DHA can be about 1:2 to about 5:1, preferably about 1:1 to about 3:1, and more preferably about 2:l. In the method of the invention the combination of DHA and ARA is preferably administered as part of an infant formula. The infant formula for use in the present invention is preferably nutritionally complete and typically contains suitable types and amounts of lipid, carbohydrate, protein, vitamins and minerals. The amount of lipid or fat typically can vary from about 3 to about 7 g/100 kcal. The amount of protein typically can vary from about 1 to about 5 g/100 kcal. The amount of carbohydrate typically can vary from about 8 to about 12 g/100 kcal. Protein sources can be any used in the art, e.g., nonfat milk, whey protein, casein, soy protein, hydrolyzed protein, amino acids, and the like. Carbohydrate sources can be any used in the art, e.g., lactose, glucose, corn syrup solids, maltodextrins, sucrose, starch, rice syrup solids, and the like. Lipid sources can be any used in the art, e.g., vegetable oils such as palm oil, soybean oil, palmolein, coconut oil, medium chain triglyceride oil, high oleic sunflower oil, high oleic safflower oil, and the like. Conveniently, commercially available infant formula can be used. For example, Enfamil®, Enfamil® Premature Formula, Enfamil® with Iron, Lactofree®, Nutramigen®, Pregestimil®, ProSobee® (available from Mead Johnson & Company, Evansville, Indiana, U.S.A.), Similac®, Isomil®, Alimentum®, Neocare®, and Similac® Special Care (available from Ross Laboratories, Columbus, Ohio, U.S.A.), may be supplemented with suitable levels of ARA and DHA at the proper ratios and used in practice of the method of the invention. The form of administration of the DHA and ARA in the method of the invention is not critical, as long as a growth enhancing amount is administered. Most conveniently, the DHA and ARA are supplemented into infant formula which is then fed to the infants. Alternatively, the DHA and ARA can be administered as a supplement not integral to the formula feeding, for example, as oil drops, sachets, in combination with other nutrient supplements such as vitamins, and the like. The growth enhancing amount of DHA is typically about 2.5 mg/kg of body weight/day to about 60 mg/kg of body weight/day, preferably about 6 mg/kg of body weight/day to about 40 mg/kg of body weight/day, more preferably about 12 mg/kg body weight day to about 30 mg/kg body weight/day, and even more preferably about 18 mg/kg of body weight/day to about 24 mg/kg of body weight/day. The growth enhancing amount of ARA is typically about 5 mg/kg of body weight/day to about 120 mg/kg of body weight/day, preferably about 12 mg/kg of body weight/day to about 80 mg/kg of body weight day, more preferably about 24 mg/kg body weight/day to about 60 mg/kg body weight/day, and even more preferably about 36 mg/kg of body weight/day to about 48 mg/kg body weight/day. The amount of DHA in infant formulas for use in the present invention typically varies from about 2 mg/100 kilocalories (kcal) to about 50 mg/100 kcal, preferably about 5 mg/100 kcal to about 33 mg 100 kcal, more preferably about 10 mg/100 kcal to about 25 mg/100 kcal, and even more preferably about 15 mg/100 kcal to about 20 mg/100 kcal. The amount of ARA in infant formula for use in the present invention typically varies from about 4 mg/100 kcal to about 100 mg/100 kcal, preferably about 10 mg/100 kcal to about 67 mg/100 kcal, more preferably about 20 mg 100 kcal to about 50 mg/100 kcal, and even more preferably about 30 mg/100 kcal to about 40 mg/100 kcal. The infant formula supplemented with oils containing DHA and ARA for use in the present invention can be made using standard techniques known in the art. For example, replacing an equivalent amount of an oil normally present, e.g., high oleic sunflower oil. The source of the ARA and DHA can be any source known in the art such as fish oil, single cell oil, egg yolk lipid, brain lipid, and the like. The DHA and ARA can be in natural form, provided that the remainder of the LC PUFA source does not result in any substantial deleterious effect on the infant. Alternatively, the DHA and ARA can be used in refined form. It is prefened that the LC PUFA used in the invention contain little or no EPA. For example, it is preferred that the infant formulas used herein contain less than about 20 mg/100 kcal EPA; preferably less than about 10 mg/kcal EPA; more preferably less than about 5 mg/100 kcal EPA; and most preferably substantially no EPA. Prefereed sources of DHA and ARA are single cell oils as taught in U.S. patent nos. 5,374,657, 5,550,156, and 5,397,591, the disclosures of which are incorporated herein by reference in their entirety. The following examples are to illustrate the invention but should not be interpreted as a limitation thereon. EXAMPLES I CLINICAL STUDY DESIGN INTRODUCTION This study is a double-blind, randomized, controlled parallel design, prospective trial of premature infant formulas containing microalgae and fungi-derived oils which contain a part of their constituents arachidonic acid and docosohexaenoic acid. Formula feeding subjects will be randomized into one of 3 feeding groups: premature formula plus DHA (about 0.13% of energy) and ARA (about 0.26% of energy) premature formula plus DHA (about 0.13% of energy) premature formula WITHOUT DHA and ARA The products have the same nutrient composition (see Appendix A) and differ only in the level of DHA and ARA. The products will be blinded. The present order of formula has no relationship to randomization. Normal, term, breast fed infants will be enrolled to provide a normal visual acuity reference. Fifty evaluable subjects will be completed in each group. Premature infants will remain on study formulas after reaching 90 kcal/kg/d for a minimum of 28 days or until hospital discharge whichever is longer. After 28 days or discharge, whichever is longer, all premature infants will receive Enfamil or Enfalac with Iron. If medically indicated, ProSobee, Lactofree, Alactamil, Nutramigen, or Pregestimil may be used in place of Enfamil or Enfalac with Iron. Term infants will receive at least 85% of their nutrition from breast milk. Primary measures of effectiveness will include visual acuity and red blood cell membrane fatty acid profiles (i.e. DHA and ARA levels). The measure of safety will be growth and adverse experience reports. SUBJECTS 2.1 SOURCE AND CHARACTERIZATION OF STUDY GROUP Acceptable preterm subjects will be relatively healthy premature infants taking preterm formula. Anticipated hospitalization should be sufficient to allow for 28 days of enteral intake ≥ 90 kcal/kg/d and ≥ 85% study formula intake. All races and both sexes will be eligible for the study. 2.2 INCLUSION CRITERIA Preterm infants Birth weight ≥ 900 g Formula feeding at time of study enrollment Anticipate enteral intake of ≥ 90 kcal/kg/day for ≥ 28 days before discharge home Informed consent obtained Term Infants: 38 to 42 weeks gestation Committed to breast feeding Informed Consent obtained 2.3 EXCLUSION CRITERIA Preterm infants ≥1500 g at birth Preterm and Term Infants: History of underlying disease or congenital malformation which in the opinion of the investigator is likely to interfere with the evaluation of the subject More than 24 days between birth and full oral feeds (≥ 90 kcal/kg/d) Small (< 10th percentile) for gestational age at birth (SGA) Necrotizing enterocolitis as diagnosed by the physician - 11 - Other gastrointestinal disease Impaired visual or ocular status at birth 2.4 CONCOMITANT MEDICATIONS, HOSPITALIZATIONS, ILLNESSES No medication which may effect FPL response may be used within 3 days of measurement. No evidence of viral of bacterial infection during FPL testing. No medications known to effect lipid metabolism (e.g., heparin at therapeutic levels) 3. STUDY PRODUCT INFORMATION 3.1 FORMULATIONS Nutrient composition is included as Appendix A. 4. STUDYPROCEDURES 4.2.1 ENROLLMENT Enrollment will take place over a 6 month period. Ideally, sufficient subjects will be enrolled so that 10 subjects in each group complete the study at each site for the multi-center trial. A total of 50 infants per formula group will complete this trial. 4.2.2 SCHEDULE OF EVENTS (SEE FLOW CHART, SECTION 8.4) 4.2.2.1 RECRUITMENT Mothers of eligible, healthy, preterm formula fed infants and term, breastfed infants will be contacted, the study explained to them, and if they are agreeable, written informed consent obtained. Term infants may be enrolled anytime from birth until or during the 48 week visit. 4.2.2.2 RANDOMIZATION Recruited formula fed subjects will be randomized into study groups. Randomization can occur anytime after enteral feeds reach 50 kcal kg/day until commencement of full enteral feeds (i.e., ..90 kcal/kg/day). 4.2.2.3 FEEDING All premature infants will receive their assigned study formula after informed consent has been granted and enteral feeds are at least 50 kcal/kg/day. The infant will remain on study formula 28 days after reaching 90 kcal kg/d or until hospital discharge, whichever is longer. Oral feeding amount, strength and rate will advance as appropriate for the clinical management of the infant. All parents will be instructed not to feed solid foods during the study. The parents will be instructed that the study formula or breast milk is to serve as the sole source of food from enrollment to study end. 4.2.2.4 BASELINE DATA COLLECTION The following data will be collected by the Investigator at the time of enrollment and randomization on the case report forms: Informed consent of parent obtained. Post conceptual age. That the subject is a premature infant, with Birth weight ≥900 gm and ≥ 1500 gm or a normal term infant between 38 and 42 weeks gestational age. That the preterm subject is receiving infant formula or term infant is committed to breast feeding. Anticipated preterm infant enteral intake of ≥90 kcal/kg/day for ≥28 days prior to discharge home. That the subject has no history of underlying disease, inborn error of metabolism, or congenital malformation which in the opinion of the Investigator is likely to interfere with the evaluation of the study formulas. That the subject is not small (< 1 Oth percentile) for gestational age at birth. That the subject does not have necrotizing enterocolitis as diagnosed by a physician. That the subject does not have a gastrointestinal disease. No more than 24 days between birth and full enteral feeds (i.e., __90 kcal/kg/day). That the subject did not have impaired visual or ocular status at birth. Birth date, sex, race. Birth weight, length and head circumference 4.2.2.5 INVESTIGATOR PERIODIC DATA COLLECTION "During hospitalization, preterm subjects will have their weight recorded daily while they are receiving study formula. Length and head circumference will be recorded weekly, along with an additional weight measurement. For a given subject, the same scale should be used for the weekly weight measurement." "Weight, length, and head circumference will also be recorded at the 40, 48, and 57 week post conceptual age visit (preterm) and 56 and 119 days of age visit (term)." 4.2.2.6 BLOOD DRAW When preterm infant enrolls in the study and again at termination of study formula (i.e., hospital discharge or 28 days after reaching 90 kcal/kg/d of study product), the Investigator will ascertain that the infant is essentially solely formula fed. If this criteria is met, 1.2 ml/blood will be drawn for blood lipids. The sample will be processed as described in Appendix B. An attempt will also be made to draw a similar blood sample at the 48 weeks PCA visit when visual acuity is measured in both term and preterm infants. 4.2.2.7 VISUAL ACUITY BY FORCED CHOICE PREFERENTIAL LOOKING (FPL) AT 48 AND 57 WEEKS ± 4 DAYS POSTCONCEPTUAL AGE When the infant is 48 and 57 weeks ± 4 days post-conceptual age, trained persons at each study site will follow the Teller Acuity Card Procedure for the measurement of visual acuity of all study subjects. It is essential that only persons who are trained in the FPL procedure for determining visual acuity do the testing. If necessary, framing of responsible persons and documentation of completion of successful training will be done at Children's Hospital Medical Center Ophthalmology Department in Seattle, Washington, according to the procedure attached as Appendix C. If the infant cannot complete the procedure at 48 or 57 weeks ± 4 days postconceptual age (i.e., too fussy, too sleepy, too inattentive) the test should be repeated within 7 days. 4.2.2.8 INTERIM EVALUATION At preterm infant hospital discharge or 28 days after reaching 90 kcal/kg/d of study formula feeding, whichever is longer, the investigator will fill out an "Interim Evaluation" form. After reviewing the subject's records and discussion with the parents and staff, the investigator will indicate whether: Whether or not the subject completed at least 28 days of study formula intake ≥90 kcal/kg/d and both blood samples obtained If the study was not completed, and reason Whether or not the subject received steroids (glucorticoids) Investigator's evaluation of the study formula The first and last dates study material was taken will be recorded. 4.2.2.9 FINAL EVALUATION At the final study visit (57 weeks postconceptual age) or earlier if the subject drops out, the Investigator will fill out a "Final Evaluation" Case Report Form. After reviewing the subject's records and discussion with the parents, the Investigator will indicate whether the subject: (1) Completed feeding regiment and all study parameters (i.e., anthropometries and visual acuity measured). (2) Did not complete feeding regimen. (3) Not completed and reason. 4.3 CLINICAL OBSERVATIONS 4.3.1 PHYSICAL EXAMINATIONS Subjects will have weight, length and head circumferences recorded at birth, weekly while hospitalized, then at 40, 48, and 57 weeks ± 4 days postconceptual age. Body weight will be measured using an electronic balance or a double beam balance accurate to 10 g or l A oz with non-detachable weights. During hospitalization, if more than one such balance is employed in the practice, either one balance should be designated the study balance and all study weights will be carried out on that balance for a particular subject, or the balances will be checked and certified to register the same weight throughout the range of weights expected. Outpatient weights will be obtained on a calibrated office scale. Documentation indicating balance calibration of the outpatient balance carried out within 12 months of study initiation will be supplied to the Sponsor. Length will be measured with the infant in recumbent position with the help of two examiners and a suitable measuring apparatus. One person holds the subject's head in contact with a fixed vertical headboard and a second person holds the subject's feet, toes pointing directly upward and, also applying gentle traction. The baby is measured from the headboard to the soles of the feet with a non-stretching tape measure. Head circumference will be measured, employing a flexible, non- stretchable cloth or vinyl tape. 4.3.2 VISUAL ACUITY BY FORCED CHOICE PREFERENTIAL LOOKING (FPL) Visual acuity will be determined at 48 and 57 weeks ± 4 days postconceptual age according to procedures outlined in Appendix C. 4.3.3 LABORATORY TESTS Blood will be drawn from preterm infants by heel prick or venipuncture when study formula is begun and terminated. An attempt will be made to draw blood at 48 weeks ± 4 days PCA from both term and preterm infants. Procedures for handling the blood are described in Appendix B. 4.4 FLOW CHART idical problems related to or affecting (ormula consumption will be recorded when they occur. jcordedΛvJeekly during hospitalization u hospital discharge or 28 days of study formula intake (after reaching 90 kcal/kg/d), whichever is later 5. CRITERIA FOR RESPONSE Criteria for response will depend upon the following: Visual Acuity better than the control formula. Visual Acuity comparable to breastfed term infant. Red Blood Cell phosphatidyl ethanolamine DHA and ARA weight % greater than formula control group. Growth as measured by weight achieved at 48 and 57 weeks postconceptual age comparable to formula control group. 6. STATISTICS 6.1 RANDOMIZATION If the subject meets the inclusion and exclusion criteria, randomization to one of three formula groups will take place. The randomization schedule will be provided by Mead Johnson Research Center. A separate randomization schedule will be provided for males and females. 6.2 SAMPLE SIZE The primary parameter of interest is visual acuity as measured by the Forced Choice Preferential Looking (FPL). The minimal clinically relevant difference was deteπnined to be 0.5 octave. A consultant in the field of visual acuity estimated the standard deviation to be 0.5 octave. This value was increased to .7 octave in case more variability was experienced in this study. Thirty-two subjects per group are needed to attain 80% power when testing at an alpha level of 0.05. A sample size estimate of 50 per group was determined to achieve cc + 0.05, β + 0.20, for weight of infants receiving study oil being greater than 400 gm below control at 48 weeks postconceptual age or 500 g below control at 57 weeks postconceptual age with a standard deviation of 800 g. It was therefore determined that 50 subjects per group will be used in the study. 6.3 ANALYTICAL PLAN Visual acuity data will be recorded in cycles per cm. These values will be converted to cycles per degree using the following formula: cycles/degree ■ = 38 x cycles/cm 55 A log transformation will be applied to the data prior to analysis. Analysis of variance techniques will be used to assess feeding regimen group differences in visual acuity. If the overall F test for feeding regimen is significant at al alpha level of 0.05, pairwise comparisons will be made at an alpha level of 0.05. If no significant differences are detected, then a post-study power analysis will be performed to demonstrate that the study had adequate power to detect the minimal clinically relevant difference. Analysis of variance will be used to assess feeding regimen differences in phosphatidyl choline DHA and ARA levels and in phosphatidyl ethanolamine DHA and ARA levels at each time point. If the overall F test is significant at al alpha level of 0.05, then pairwise comparisons will be made at an alpha level of 0.05. Analysis of variance will be used to assess feeding regiment differences in weight at 48 and 57 weeks postconceptual age. The statistical model will include terms for feeding regimen, study center, sex and all two-way interactions. Non-significant interactions will be removed from the final statistical model. Two one-sided tests will be performed comparing each experimental formula (EC) with the control formula (CF). The hypothesis to be tested is as follows: H 0 = Weight (CF) ≤ Weight (EF). The alternative hypothesis is as follows: H, = Weight (CF) > Weight (EF). If Ho if rejected and the mean weight of the control formula exceeds that of the experimental formula by more than 400 mg at 48 weeks postconceptual age or by 500 g at 57 weeks postconceptual age then the conclusion is that the experimental formula does not exceed that of the experimental formula by more than 400 g at 48 weeks postconceptual age or by 500 mg at 57 weeks postconceptual age then the conclusion is that the experimental formula does provide adequate growth. If H 0 is not rejected then a post-study power analysis will be performed to demonstrate that eh study had adequate power to detect the above mentioned clinically relevant differences. If adequate power is achieved then the conclusion is that the experimental formula does provide adequate growth. Fisher's exact test will be used to compare the proportion of subjects in each group with illness/symptoms of concern during the study. The analysis will be performed for each type of illness/symptom reported, with classification of investigator terms into similar terminology made as necessary. APPENDIX A NUTRIENT COMPOSITION OF FORMULAS All study formulas are 24 kcal fl oz and are idenUcal in composition to marketed Enfamil Premature Formula except for the study oils employed. These oils are described in the protocol. π FINAL STUDY REPORT Study Design: This double-blind, parallel- group study (project 3338) was carried out in 16 neonatal centers (study numbers 9698-9709, 9712, 9723, 9743, and 9746) in North America. Three premature infant feedings were compared. Each had the same composition except for the incorporation of fungal and/or micro algal oils up to about 3% of the fat blend to provide the experimental levels of docosahexaenoic acid (DHA) and arachidonic acid (ARA). The control formula (C, Enfamil® Premature Formula) contained no DHA or ARA, the DHA formula (D) contained about 0.15% of energy as DHA (0.34% of fat), and the DHA+ARA formula (DA) contained about 0.14% of energy as DHA (0.33% of fat) and 0.27% of energy as ARA (0.60% of fat). The formulas were fed to 284 randomized infants weighing 846 to 1560 grams at birth for at least 28 days. Upon completion of study formula intake, they were given routine infant formula and followed through 4 months gestationally conected age. A group of 90 exclusively human milk fed term infants were enrolled and followed to 4 months of age as a reference group (H). Study Objective and Statistical Analysis; The primary objective of this study was to establish the safety of feeding D or DA to preterm infants during their initial hospitalization as measured 1) by growth, acceptance and tolerance while consuming the formula for at least 1 month and 2) by close monitoring and observation for a 4 to 5 month follow-up period (4-5 times the treatment period) while consuming unsupplemented routine term infant formula. The primary growth parameter selected was weight with evaluation of the proposition that weight on test formula was greater than or equal to weight on control formula. The one sided statistical test for an adverse effect on growth maximized the power to detect a difference should one be present. A two-sided test was used for all other parameters. A p-value of less than 0.05 was used to establish significance. Secondary objectives of the study were 1) to evaluate the impact of fatty acid levels in erythrocyte phospholipids at the end of study feeding and 2) to determine if any effect on mean visual acuity greater than half an octave could be demonstrated at 2 and 4 months corrected age. Results: Six infants were just outside the weight parameters and five infants just older than the less than 24 days chronological age parameter for enrollment in the study. In each case, judgement by the clinical or medical monitor was made to include them in the study prior to enrollment based on their homogeneity with other study infants in all other particulars, e.g., state of health, type of medical complications, and weight for gestational age. All these infants were included in the analysis of the study results. The formula groups were comparable at enrollment (See table 1). Post-conceptual age, weight, length, and head circumference at enrollment did not differ among the groups. AH groups experienced comparable final study status (See table 2). Drop outs did not differ among the formula fed groups during hospitalization. There also were no differences in drop outs among the four groups at study completion. Both formulas D and DA provide adequate growth when compared to formula C (See table 3, figure 1, and Appendix 1). Weight gain during hospitalization was no less on D or DA than on C, 33.3, 34.7, and 30.7 g/day, respectively. Furthermore, no less weight was achieved on D or DA than on C at 40, 48, and 57 weeks post-conceptual age (See table 4, figure 2, and Appendix 1); statistical power was greater than 0.89 to detect a clinically relevant decrease. Post-hoc analysis reveals that infants on DA grew faster than infants receiving C and D (See table 5 and figure 1). This enhanced growth provided faster "premature infant catch-up" compared to C and D. Weight achieved by the DA group (3198 g) was higher than C (3075 g) and D (3051 g) at 40 weeks post-conceptual age but had not fully caught up to the term birth weight (3438 g) of group H (See table 4 and figure2). This catch up trend continued through 48 to 57 weeks by which time the mean weight of group DA did not differ from group H while groups C and D remained significantly lower. Length was not different among the formula groups either during hospitalization or the follow-up period, although the ordered sequence of mean lengths was the same as for the weights (See table 7 and figure 3). This is likely at least partially due to length being a less sensitive parameter of growth than weight. For the same reason, the mean lengths of group H infants were higher than that of all the premature infant groups at 40, 48 and 57 weeks post-conceptual age indicating slower catch up in this parameter. Head circumference is the least sensitive parameter of growth and was not different among any of the four groups at any time measured except at 40 weeks postconceptual age (See table 8 and figure 4). At this time, as expected, the birth head circumference of group H was smaller than the formula fed premature infants possibly due to molding of labor and to insufficient time for adjustment to the extrauterine environment. Visual acuity has reportedly been enhanced in studies where DHA supplemented formulas were fed to premature infants both in the hospital and continuing after discharge. In this study, visual acuity was measured about 3 months and then about 5 months after stopping study formula to determine whether a residual beneficial effect of at least half an octave might be observed. Although no difference in visual acuity was found among the formula groups at these times (See table 8 and figure 5), the acuity card method used, the length of study formula feeding, and or the length of time not on study formula at the time of measurement may have precluded its detection. However, at 57 weeks post-conceptual age, the breast fed term infant group did have statistically higher visual acuity scores than the test formula groups. But even these differences were at most only 0.33 octave and were clinically insignificant (See figure 6). It is important to note that the breast fed infants continued to receive DHA and ARA during the 3-5 month follow-up period while the formula fed groups did not. Thus, this minor difference in performance was not unexpected based on previous study findings and on developmental differences between term and preterm infants even at the same gestational age. Individual fatty acid levels were determined in the phosphatidylcholine and phosphatidylethanolamine fractions of red blood cells before formula feeding, at the conclusion of test formula feeding, and at 48 weeks post-conceptual age (See tables 9 and 10). The premature infant groups were comparable at the beginning of test formula feeding. At the conclusion of test formula feeding, individual fatty acid levels varied among the groups. DHA and ARA were statistically significantly higher in the respectively supplemented groups. Other fatty acid levels reflected the impact of the supplementation. No clinically significant alterations in fatty acid levels or metabolism were identified. After discontinuing study formula and consuming a diet without DHA or ARA for about 3 months, no differences in fatty acid levels among formula fed groups were detectable, except for phosphatidylethanolmine levels of 18:2 (range 8.9-9.3%) and DHA (range 3.2-4.1%) which differences were not identified as being clinically significant. However, the breast fed group shows statistically significant differences in 13 fatty acid levels compared to the formula fed infants. These differences are undoubtedly due to the differences in fatty acid composition of human milk and the term formulas including the lack of DHA and ARA in the latter. Preterm infant complications were similar in all groups (See table 11). Over 80% of all infants were op hthamo logically examined and over 90% had ultrasound evaluation of their heads. Specifically, the incidence and severity of retinopathy of prematurity (ROP or retrolental fibroplasia/RLF) and the incidence of intraventricular hemonhage or its complications did not differ among formula groups. No feeding group related complications were identified. Serious adverse experiences did not differ (p=0.93) among the formula groups and were in the range of those expected in a premature infant population while on study formula: 6% in group C, 5% in group D, and 6% in group DA (See table 12). After the experimental formula phase, serious adverse experiences still did not differ among the preterm groups (See table 13): 13% in group C, 15% in group D, and 15% in group DA. However, the term infant breast fed group had significantly fewer serious adverse experiences (1%, p=0.002) as expected. Two infants reportedly suffered sudden infant death syndrome (SEDS), one in group C and one in group D; there was no significant difference in this complication among all four groups. Conclusions: We conclude that feeding 0.13% of calories as DlrϊA from micro algal oil and feeding 0.13 % of calories as DHA from micro algal oil plus 0.26% of calories as ARA from fungal oil in the matrix of premature infant formula to premature infants during the period of their initial hospitalization prior to 40 weeks post conceptual age is safe. These micro algal and fungal oil supplements do not result in any adverse effect on growth, clinical complications, or untoward events. Furthermore, this study reveals that growth benefits accrue to premature infants fed Enfamil Premature Formula supplemented with DHA and ARA from these sources compared to unsupplemented formula or formula supplemented with only DHA. No measurable benefit on visual acuity was identified when infants were tested at about 3 and 5 months after the supplemented formula was discontinued (2 and 4 months conected age). However, providing human milk levels of intake of long chain polyunsaturated acids are wananted because they are critical to brain development and foster enhanced catch-up growth during this early development period. Table 1 Birth Statistics of Premature Subjects Table 2 Summary of Final Study Status •The CRFs for 9709-003 (DHA) and 9743-304 (DHA) were marked discontinued because the subjects met the study formula intake criteria for only 27 days. These subjects are counted completed here because subjects at other sites -with similar intakes were marked completed. •-"Based on subjects who completed the Study Formula phase. During the Term Formula phase, subjects were fed marketed formula. Switching to a different marketed formula did not result in termination from the Term Formula phase. Table 3 Weight Growth Rate During Study Formula Phase Least Square Standard Comparison Study Gender Gender-by-Regi en Regimen n Mean Error Comparison p-value* p-value p-value p-value Control 60 30.7 1.1 Control vs DHA 0.967 0.00 0.17 0.87 DMA 65 33.3 1.1 Control vs DHA+ARA 0.998 DHA+ARA 66 34.7 1.1 I IX) -J I * One-s ided test of the nul l hypothes i s: Test Mean >= Control Mean Table 4 Wei ght at 40, 48, and 57 Weeks Post- Conceptual Age Weeks Post-Conceptual Least Square Standard Comparison Study Gender Gender-by-Regimen Age Regimen n Mean Error Comparison p-value* p-value p- alue p-value 40 Control 52 3075.3 67.9 Control vs DHA 0.388 0.59 0.45 1.00 DHA 54 3051.4 66.8 Control vs DHA+ARA 0.931 DHA+ARA 59 3198.2 62.9 HH vs DHA 0.000 HH 90 3437.7 60.6 HH vs DHA+ARA 0.001 HH vs Control 0.000 48 Control 53 4711.0 94.6 Control vs DHA 0.360 0.58 0.13 0.29 DHA 51 4663.8 97.3 Control vs DHA+ARA 0.995 DHA+ARA 57 5039.1 93.0 HH vs DHA 0.000 HH 81 5181.5 85.9 HH vs DHA+ARA 0.114 HH vs Control 0.000 57 Control 47 6045.4 139.5 Control vs DHA 0.371 0.58 0.29 0.33 DHA 49 5987.2 137.6 Control vs DHA+ARA 0.940 DHA+ARA 55 6312.9 127.9 HH vs DHA 0.005 HM 76 6405.0 126.7 HH vs DHA+ARA 0.278 HH vs Control 0.014 * One- sided test of the nul l hypothes i s : Test Hean >= Control Hean Table 5 Post-hoc Analysis of Weight Table 6 Length at 40, 48, and 57 Weeks Post-Conceptual Age Weeks Pairwise Study Gender Gender-by-Regimen Least Square Standard Regimen Pairwise Post-Conceptual p-value p-value p-value p-value Age Regimen n Mean Error p-value Comparison 0.03 0.88 0.63 40 Control 52 48.4 0.4 0.000 Control vs DHA 0.242 0.233 DHA 54 47.8 0.4 Control vs DHA+ARA DHA+ARA 58 49.0 0.4 HH vs DHA 0.000 0.000 HH 89 50.6 0.4 HH vs DHA+ARA Control vs HH 0.000 DHA vs DHA+ARA 0.017 000 Control vs DHA 0.824 0.00 0.14 0.52 48 Control 53 54.7 0.3 0. Control vs DHA+ARA 0.079 DHA 52 54.6 0.3 55.5 0.3 HH vs DHA 0.000 DHA+ARA 57 HH vs DHA+ARA 0.000 HH 81 57.4 0.3 Control vs HH 0.000 DHA vs DHA+ARA 0.050 I 0.615 0.00 0.02 0.84 o 57 Control 47 60.7 0.4 0.000 Control vs DHA A+ARA 0.236 DHA 49 60.5 0.4 Control vs DH HH vs DHA 0.000 DHA+ARA 54 61.3 0.3 HH vs DHA+ARA 0.006 HH 76 62.4 0.3 Control vs HH 0.000 DHA vs DHA+ARA 0.087 Tabl e 7 Head C i rcumference at 40 , 48, and 57 Weeks Post-Conceptual Age Weeks Study Gender Gender-by-Regimen Standard Regimen Pairwise Pairwise Post-Conceptual Least Square p-value Comparison p-value p-value p-value p-value Age Regimen n Mean Error ontrol 51 35.4 0.2 0.000 Control vs DHA 0.931 0.91 0.00 0.38 40 C Control vs DHA+ARA 0.900 DHA 53 35.4 0.2 HH vs DHA 0.000 DHA+ARA 58 35.5 0.2 HH vs DHA+ARA 0.000 HH 85 34.5 0.2 Control vs HM 0.000 DHA vs DHA+ARA 0.829 0.81 0.00 1.00 0.983 48 Control 52 39.1 0.2 DHA 51 39.0 0.2 DHA+ARA 56 39.0 0.2 81 39.0 0.1 HH 0.64 0.00 0.85 O 0.689 57 Control 47 41.9 0.2 DHA 49 41.6 0.2 DHA+ARA 53 41.7 0.2 76 41.7 0.2 HH Table 8 Visual Acuity at 48 and 57 Weeks Post-Conceptual Age d Ueeks Geometric Least Square Standar Hean Error Regimen Pairwise Pairwise Study Post-Conceptual mean p-value Age Regimen n (cyctes/deg) (log base2 eye I .es /deg) (octaves) p-value Comparison p-value 0.950 0.000 48 Control 51 1.72 0.78 0.10 0.85 0.10 DHA 50 1.80 DHA+ARA 57 1.72 0.78 0.09 1.75 0.81 0.09 HH 81 0.000 1.79 0.08 0.004 Control vs DHA 0.697 57 Control 46 3.47 ol vs DHA+ARA 0.071 DHA 47 3.37 1.75 0.08 Contr I 1.61 0.07 HH vs DHA 0.042 DHA+ARA 55 3.06 OJ 1.94 0.07 HH vs DHA+ARA 0.000 r- HH 77 3.85 Control vs HH 0.113 I DHA vs DHA+ARA Table 9 Red Blood Cell Phosp atidytcholine Fatty Acids Fatty Arithmetic Standard Regimen Pairwise Pairwise Time Acid Regimen n Hean Error Median p-value Comparison p-value Study Form Initiation 12:0 Control 52 0.081 0.019 0.036 0.762 DHA 58 0.066 0.013 0.030 DHA+ARA 61 0.057 0.009 0.031 Study Form Initiation 14:0 Control 52 0.623 0.036 0.599 0.559 DHA 58 0.663 0.031 0.686 DHA+ARA 61 0.661 0.031 0.656 Study Form Initiation 14:1 Control 52 0.045 0.009 0.021 0.165 DHA 58 0.026 0.005 0.016 DHA+ARA 61 0.035 0.006 0.018 Study Form Initiation 16:0 Control 52 36.706 0.540 36.594 0.884 DHA 58 36.363 0.462 35.578 DHA+ARA 61 36.877 0.445 35.987 I OJ Study Form Initiation 16:1 Control 52 0.940 0.049 0.845 0.441 o DHA 58 0.981 0.050 0.976 DHA+ARA 61 1.094 0.064 0.931 Study Form Initiation 18:0 Control 52 11.660 0.243 11.468 0.243 DHA 58 11.402 0.238 11.201 DHA+ARA 61 11.016 0.192 11.174 Study Form Initiation 18:1 Control 52 17.053 0.298 17.308 0.679 DHA 58 17.219 0.391 16.935 DHA+ARA 61 17.256 0.271 16.988 Study Form Initiation 18:2 Control 52 18.614 0.525 18.952 0.830 DHA 58 18.631 0.505 19.603 DHA+ARA 61 18.573 0.466 18.824 Study Form Initiation 18:3n6 Control 52 0.120 0.008 0.116 0.034 Control vs DHA 0.196 DHA 58 0.136 0.008 0.130 Control vs DHA+ARA 0.010 DHA+ARA 61 0.150 0.009 0.134 DHA VS DHA+ARA 0.176 Table 9 Red Blood Cell Phosphatidylchol ine Fatty Acids Fatty Arithmetic Standard Regimen Pairwise Pairwise Time Acid Regimen n Mean Error Median p-value Comparison p-value Study Form Initiation 20:0 Control 52 0.399 0.050 0.224 0.647 DHA 58 0.337 0.035 0.236 DHA+ARA 61 0.310 0.037 0.188 Study Form Initiation 18:3n3 Control 52 0.315 0.033 0.246 0.234 DHA 58 0.257 0.014 0.246 DHA+ARA 61 0.233 0.010 0.216 Study Form Ini iation 20:1 Control 52 0.287 0.020 0.262 0.723 DHA 58 0.287 0.015 0.281 DHA+ARA 61 0.268 0.011 0.269 Study Form Initiation 18:4 Control 52 0.017 0.003 0.000 0.290 DHA 58 0.025 0.004 0.017 DHA+ARA 61 0.017 0.003 0.008 J Study Form Initiation 20:2n6 Control 52 0.632 0.025 0.632 0.673 I DHA 58 0.628 0.025 0.640 DHA+ARA 61 0.602 0.021 0.614 Study Form Initiation 20:3n6 Control 52 2.144 0.098 2.096 0.507 DHA 58 2.208 0.080 2.296 DHA+ARA 61 2.218 0.074 2.135 Study Form Initiation 20:4n6 Control 52 7.657 0.262 8.124 0.819 DHA 58 8.164 0.347 7.876 DHA+ARA 61 8.090 0.310 8.207 Study Form Initiation 22:1 Control 52 0.106 0.010 0.105 0.155 DHA 58 0.127 0.010 0.130 DHA+ARA 61 0.126 0.010 0.139 Study Form Initiation 20:5n3 Control 52 0.351 0.057 0.298 0.911 DHA 58 0.322 0.015 0.302 DHA+ARA 61 0.321 0.015 0.329 Table 9 Red Blood Cell Phosphati dylcholine Fatty Acids Fatty Arithmetic Standard Regimen Pai rwise Pai rwise Ti e Acid Regimen n Hean Error Median p-value Comparison p-value Study Form Initiation 22:4n6 Control 52 0.578 0.144 0.423 0.331 DHA 58 0.493 0.030 0.481 DHA+ARA 61 0.443 0.021 0.425 Study Form Initiation 24:1 Control 52 0.208 0.054 0.075 0.665 DHA 58 0.115 0.019 0.084 DHA+ARA 61 0.180 0.056 0.096 Study Form Initiation 22:5n6 Control 52 0.266 0.020 0.232 0.923 DHA 58 0.259 0.017 0.239 DHA+ARA 61 0.265 0.018 0.256 Study Form Initiation 22:4n3 Control 52 0.000 0.000 0.000 0.199 DHA 58 0.001 0.001 0.000 DHA+ARA 61 0.002 0.001 0.000 ■ oo Study Form Initiation 22:5n3 Control 52 0.213 0.019 0.203 0.885 on DHA 58 0.215 0.013 0.195 I DHA+ARA 61 0.203 0.010 0.193 Study Form Initiation 22:6n3 Control 52 0.984 0.051 1.000 0.858 DHA 58 1.075 0.053 1.034 DHA+ARA 61 1.006 0.050 0.970 Table 9 Red Blood Cell Phosphatiidylcholine Fatty Acids Standard Regimen Pairwise Pairwise Fatty Arithmetic Comparison p-value Time Acid Regimen n Mean Error Median p-value .026 0.035 0.843 Study Form Termination 12:0 Control 53 0.100 0 DHA 56 0.111 0.042 0.031 DHA+ARA 59 0.064 0.012 0.032 0.039 0.806 0.834 Study Form Termination 14:0 Control 53 0.808 DHA 56 0.781 0.035 0.783 DHA+ARA 59 0.755 0.036 0.758 0.008 0.033 0.155 Study Form Termination 14:1 Control 53 0.047 DHA 56 0.036 0.009 0.015 DHA+ARA 59 0.036 0.007 0.018 0.512 34.798 0.767 Study Form Termination 16:0 Control 53 35.837 DHA 56 35.560 0.595 34.841 I DHA+ARA 59 35.069 0.584 33.890 o σs 0.118 I Study Form Termination 16:1 Control 53 0.566 0.026 0.526 0.013 Control vs DHA ARA 0.003 DHA 56 0.594 0.042 0.475 Control vs DHA+ DHA vs DHA+ARA 0.152 DHA+ARA 59 0.526 0.029 0.472 0.261 14.197 0.886 Study Form Termination 18:0 Control 53 13.972 DHA 56 14.065 0.237 13.867 DHA+ARA 59 14.341 0.253 14.108 0.277 14.291 0.686 Study Form Termination 18:1 Control 53 14.456 DHA 56 14.116 0.272 13.998 DHA+ARA 59 14.344 0.380 14.218 0.600 Study Form Termination 18:2 Control 53 21.673 0.340 21.506 0.001 Control vs DHA vs DHA+ARA 0.005 DHA 56 22.045 0.457 22.517 Control DHA VS DHA+ARA 0.001 DHA+ARA 59 19.899 0.337 20.662 53 0.080 0.006 0.074 0.527 Study Form Termination 18:3n6 Control DHA 56 0.088 0.009 0.076 DHA+ARA 59 0.087 0.013 0.066 Table 9 Red Blood Cell Phosphat idylchol ine Fatty Acids Fatty Arithmetic Standard Regimen Pairwise Pairwise Ti e Acid Regimen n Mean Error Median p-value Comparison p-value Study Form Termination 20:0 Control 53 0.504 0.050 0.392 0.424 DHA 56 0.472 0.053 0.281 DHA+ARA 59 0.430 0.049 0.251 Study Form Termination 18:3n3 Control 53 0.321 0.020 0.283 0.031 Control vs DHA 0.503 DHA 56 0.335 0.030 0.285 Control vs DHA+ARA 0.068 DHA+ARA 59 0.273 0.009 0.256 DHA VS DHA+ARA 0.011 Study Form Termination 20:1 Control 53 0.318 0.014 0.302 0.149 DHA 56 0.300 0.013 0.283 DHA+ARA 59 0.307 0.013 0.283 Study Form Termination 18:4 Control 53 0.022 0.004 0.015 0.672 DHA 56 0.022 0.003 0.018 DHA+ARA 59 0.014 0.002 0.008 I OO Study Form Termination 20:2n6 Control 53 0.893 0.026 0.910 0.051 DHA 56 0.880 0.023 0.873 DHA+ARA 59 0.824 0.022 0.821 Study Form Termination 20:3n6 Control 53 2.032 0.073 2.091 0.208 DHA 56 2.017 0.070 2.043 DHA+ARA 59 1.908 0.064 1.904 Study Form Termination 20:4n6 Control 53 6.046 0.240 6.029 0.000 Control vs DHA 0.097 DHA 56 5.774 0.220 5.892 Control vs DHA+ARA 0.000 DHA+ARA 59 8.465 0.255 8.891 DHA vs DHA+ARA 0.000 Study Form Termination 22:1 Control 53 0.117 0.010 0.125 0.946 DHA 56 0.110 0.009 0.114 DHA+ARA 59 0.115 0.011 0.104 Study Form Termination 20:5n3 Control 53 0.214 0.022 0.189 0.000 Control vs DHA 0.004 DHA 56 0.246 0.012 0.233 Control vs DHA+ARA 0.108 DHA+ARA 59 0.186 0.014 0.169 DHA vs DHA+ARA 0.000 Table 9 Red Blood Cell Phosphatidylcholine Fatty Acids Fatty Arithmetic Standard Regimen Pairwise Pairwise p-value Hean Error Median p-value Comparison Ti e Acid Regimen 0.048 0.390 0.093 Study Form Termination 22:4n6 Control 53 0.484 DHA 56 0.489 0.061 0.426 DHA+ARA 59 0.496 0.027 0.487 0.039 0.062 0.303 Study Form Termination 24:1 Control 53 0.127 DHA 56 0.143 0.036 0.086 DHA+ARA 59 0.177 0.040 0.089 0.013 0.163 0.006 Control vs DHA 0.005 Study Form Termination 22:5n6 Control 53 0.181 DHA 56 0.145 0.011 0.133 Control vs DHA+ARA 0.895 DHA+ARA 59 0.172 0.009 0.165 DHA vs DHA+ARA 0.006 0.001 0.000 0.359 Study Form Termination 22:4n3 Control 53 0.001 DHA 56 0.001 0.001 0.000 DHA+ARA 59 0.003 0.002 0.000 I oo oo 0.019 0.2 Study Form Termination 22:5n3 Control 53 0.306 89 0.221 I DHA 56 0.293 0.026 0.260 DHA+ARA 59 0.265 0.013 0.255 Study Form Termination 22:6n3 Control 53 .895 0.072 0.812 0.000 Control vs DHA 0.000 DHA 56 .380 0.063 1 .352 Control vs DHA+ARA 0.000 DHA+ARA 59 .244 0.049 1.259 DHA vs DHA+ARA 0.141 Table 9 Red Blood Cell Phosphatidylcholine Fatty Acids Fatty Arithmet Standard Regimen Pairwise Pairwise Time Acid Regimen n Hean Error Median p-value Comparison p-value Weeks PCA 12:0 Control 37 0.032 0.005 0.026 0.729 DHA 32 0.028 0.006 0.016 DHA+ARA 38 0.026 0.004 0.021 HH 56 0.059 0.016 0.020 Weeks PCA 14 :0 Control 37 0.402 0.039 0.331 0.943 DHA 32 0.353 0.032 0.324 DHA+ARA 38 0.353 0.024 0.328 HM 56 0.381 0.026 0.335 Ueeks PCA 14: 1 Control 37 0.025 0.006 0.013 0.448 DHA 32 0.026 0.007 0.011 DHA+ARA 38 0.026 0.006 0.015 HM 56 0.024 0.003 0.020 Ueeks PCA 16:0 Control 37 34.627 0.577 34.319 0.000 Control vs DHA 0.527 DHA 32 35.272 0.689 34.473 Control vs DHA+ARA 0.593 DHA+ARA 38 34.802 0.506 34.165 HM vs DHA 0.000 HM 56 33.037 0.506 32.228 HH vs DHA+ARA 0.000 Control vs HM 0.000 DHA vs DHA+ARA 0.906 Weeks PCA 16: 1 Control 37 0.435 0.043 0.338 0.000 Control vs DHA 0.524 DHA 32 0.380 0.023 0.352 Control vs DHA+ARA 0.467 DHA+ARA 38 0.395 0.024 0.368 HH vs DHA 0.000 HM 56 0.507 0.020 0.473 HH vs DHA+ARA 0.006 Control vs HM 0.000 DHA vs DHA+ARA 0.183 Table 9 Red Blood Cell Phosphatidylcholine Fatty Acids Fatty Arithmetic Standard Regimen Pairwise Pairwise Time Acid Regimen n Mean Error Median p-value Comparison p-value Weeks PCA 18:0 Control 37 13.016 0.313 12.759 0. 000 Control vs DHA 0.760 DHA 32 12.944 0.249 12.786 Control vs DHA+ARA 0.889 DHA+ARA 38 12.804 0.235 12.793 HH vs DHA 0.000 HM 56 14.583 0.287 14.729 HM vs DHA+ARA 0.000 Control vs HM 0.000 DHA vs DHA+ARA 0.661 Weeks PCA 18: 1 Control 37 17.894 0.453 18.636 0.256 DHA 32 17.766 0.429 18.492 DHA+ARA 38 17.850 0.289 18.227 HH 56 18.662 0.305 18.727 Weeks PCA 18:2 Control 37 23.469 0.518 23.552 0.000 Control vs DHA 0.840 I DHA 32 23.538 0.516 ■ 23.717 Control vs DHA+ARA 0.527 DHA+ARA 38 23.738 0.422 23.839 HM vs DHA 0.000 I HM 56 18.650 0.344 18.482 HM vs DHA+ARA 0.000 Control vs HM 0.000 DHA vs DHA+ARA 0.685 Weeks PCA 18:3n6 Control 37 0.071 0.008 0.061 0.002 Control vs DHA 0.950 DHA 32 0.069 0.005 0.067 Control vs DHA+ARA 0.774 DHA+ARA 38 0.069 0.006 0.062 HM vs DHA 0.004 HM 56 0.042 0.004 0.039 HH vs DHA+ARA 0.001 Control vs HM 0.003 DHA vs DHA+ARA 0.831 Weeks PCA 20:0 Control 37 0.348 0.075 0.197 0.785 DHA 32 0.339 0.061 0.206 DHA+ARA 38 0.304 0.061 0.172 HM 56 0.409 0.044 0.215 Table 9 Red Blood Cell Phosphatidylcholine Fatty Acids Fatty Arithmet Standard Regimen Pairwise Pairwise Time Acid Regimen n Hean Error Median p-value Comparison p-value Weeks PCA 18:3n3 Control 37 0.222 0.019 0.182 0.001 Control vs DHA 0.812 DHA 32 0.211 0.015 0.182 Control vs DHA+ARA 0.918 DHA+ARA 38 0.203 0.010 0.190 HM vs DHA 0.001 HM 56 0.182 0.022 0.120 HM vs DHA+ARA 0.002 Control vs HM 0.001 DHA vs DHA+ARA 0.737 Weeks PCA 20:1 Control 37 0.418 0.019 0.420 0.000 Control vs DHA 0.579 DHA 32 0.406 0.025 0.435 Control vs DHA+ARA 0.588 DHA+ARA 38 0.382 0.016 0.375 HM vs DHA 0.001 HM 56 0.311 0.014 0.309 HM vs DHA+ARA 0.001 Control vs HM 0.000 DHA vs DHA+ARA 0.974 Weeks PCA 18:4 Control 37 0.018 0.005 0.000 0.010 Control vs DHA 0.822 I DHA 32 0.016 0.004 0.000 Control vs DHA+ARA 0.161 DHA+ARA 38 0.007 0.002 0.000 HM vs DHA 0.039 HM 56 0.024 0.004 0.015 HM vs DHA+ARA 0.001 Control vs HM 0.054 DHA vs DHA+ARA 0.262 Weeks PCA 20:2n6ι Control 37 0.543 0.023 0.537 0.629 DHA 32 0.557 0.032 0.543 DHA+ARA 38 0.636 0.053 0.550 HH 56 0.560 0.014 0.531 Weeks PCA 20 :3n6 Control 37 1.709 0.086 1.741 0.000 Control vs DHA 0.610 DHA 32 1.702 0.073 1.684 Control vs DHA+ARA 0.735 DHA+ARA 38 1.844 0.090 1.717 HM vs DHA 0.000 HM 56 2.265 0.086 2.166 HH vs DHA+ARA 0.000 Control vs HH 0.000 DHA vs DHA+ARA 0.405 Table 9 Red Blood Cell Phosphatidylcholine Fatty Acids Fatty Arithmetic Standard Regimen Pairwise Pairwise Ti e Acid Regimen n Hean Error Hedian Comparison p-value Weeks PCA 20:4n6 Control 37 4.738 0.255 4.736 0.000 Control vs DHA 0.508 DHA 32 4.475 0.196 4.499 Control vs DHA+ARA 0.805 DHA+ARA 38 4.550 0.185 4.746 HH vs DHA 0.000 HH 56 7.408 0.250 7.666 HH vs DHA+ARA 0.000 Control vs HM 0.000 DHA VS DHA+ARA 0.672 Weeks PCA 22:1 Control 37 0.166 0.036 0.131 0.664 DHA 32 0.116 0.014 0.118 DHA+ARA 38 0.131 0.024 0.105 HH 56 0.160 0.030 0.104 Weeks PCA 20:5n3 Control 37 0.102 0.015 0.077 0.000 Control vs DHA 0.633 DHA 32 0.084 0.006 0.083 Control vs DHA+ARA 0.086 DHA+ARA 38 0.099 0.009 0.078 HH vs DHA 0.000 r I HM 56 0.138 0.009 0.123 HH vs DHA+ARA 0.000 Control vs HM 0.000 DHA vs DHA+ARA 0.239 Weeks PCA 22:4n6 Control 37 0.426 0.059 0.373 0.244 DHA 32 0.382 0.029 0.417 DHA+ARA 38 0.440 0.054 0.384 HM 56 0.406 0.022 0.377 Weeks PCA 24:1 Control 37 0.247 0.070 0.112 0.000 Control vs DHA 0.337 DHA 32 0.210 0.062 0.116 Control vs DHA+ARA 0.247 DHA+ARA 38 0.179 0.055 0.108 HM vs DHA 0.000 HH 56 0.115 0.020 0.079 HH VS DHA+ARA 0.000 Control vs HH 0.000 DHA vs DHA+ARA 0.878 Table 9 Red Blood Cell Phosphatidylcholine Fatty Acids Pairwise Pairwise Standard Regimen Fatty Arithmetic Error Median p-value Comparison p-value Time Acid Regimen n Hean 0.505 0.210 0.016 0.212 0.000 Control vs DHA Weeks PCA 22:5n6 Control 37 0.186 Control vs DHA+ARA 0.647 DHA 32 0.189 0.012 00 DHA+ARA 38 0.231 0.022 0.198 HH vs DHA 0.0 HH vs DHA+ARA 0.001 0.016 0.265 HM 56 0.264 Control vs HH 0.000 DHA vs DHA+ARA 0.270 0.000 0.000 0.000 1.000 Weeks PCA 22:4n3 Control 37 DHA 32 0.000 0.000 0.000 0.000 DHA+ARA 38 0.000 0.000 00 0.000 HM 56 0.000 0.0 I 2:5n3 Control 37 0.286 0.029 0.260 0.000 Control vs DHA 0.598 Ueeks PCA 2 Control vs DHA+ARA 0.759 oo DHA 32 0.253 0.017 0.251 I HM vs DHA 0.000 DHA+ARA 38 0.268 0.026 0.256 0.000 314 HM vs DHA+ARA HH 56 0.339 0.018 0. Control vs HM 0.000 DHA vs DHA+ARA 0.BU 0.000 Control vs DHA 0.111 0.595 0.047 Weeks PCA 22:6n3 Control 37 0.569 676 Control vs DHA+ARA 0.052 DHA 32 0.685 0.048 0. HM vs DHA 0.000 DHA+ARA 38 0.662 0.043 0.663 HM V S DHA+ARA 0.000 HM 56 1.475 0.081 1.333 Control vs HM 0.000 DHA vs DHA+ARA 0.776 •-- <u I SOΞ>- m > a. α. tu c a < < tΛ tΛ + > > ** E• -& α o > c c o < u a c E — • o cα ^o ro ■ «- »- ro m - r- o ro *— c vn o -j- in ^ »0 m o o o c ' ε — * .— _ o -o R σ o o o -σ ■ s. c . — . — . — O OJ r-- R o o * -• .- «— • " — o o _ . <: < • < • __ < _ _ o o o o < < < o < oc o < cc o <c o oc o α <: u < < Table 10 Red Blood Cell Phosphatidylethanolamine Fatty Acids Fatty Arithmetic Standard Regimen Pairwise Pairwise Ti e Acid Regimen ' n Mean Error Median p-value Comparison p-value Study Form Initiation 20:0 Control 52 0.372 0.043 0.291 0.151 DHA 57 0.314 0.030 0.244 DHA+ARA 61 0.259 0.024 0.186 Study Form Initiation 18:3n3 Control 52 0.305 0.023 0.261 0.641 DHA 57 0.269 0.018 0.249 DHA+ARA 61 0.257 0.016 0.225 Study Form Initiation 20:1 Control 52 0.573 0.036 0.517 0.395 DHA 57 0.615 0.034 0.555 DHA+ARA 61 0.571 0.027 0.544 Study Form Initiation 18:4 Control 52 0.025 0.005 0.000 0.371 DHA 57 0.031 0.004 0.025 DHA+ARA 61 0.030 0.007 0.021 I Study Form Initiation 20:2n6 Control 52 0.479 0.023 0.480 0.706 oπ DHA 57 0.463 0.024 0.437 DHA+ARA 61 0.443 0.028 0.427 Study Form Initiation 20:3n6 Control 52 1.843 0.072 1.829 0.099 DHA 57 1.965 0.077 1.820 DHA+ARA 61 1.973 0.064 1.911 Study Form Initiation 20:4n6 Control 52 25.817 0.618 26.820 0.353 DHA 57 26.475 0.611 27.376 DHA+ARA 61 26.747 0.645 27.708 Study Form Initiation 22:1 Control 52 0.150 0.017 0.138 0.572 DHA 57 0.167 0.015 0.151 DHA+ARA 61 0.168 0.017 0.141 Study Form Initiation 20:5n3 Control 52 0.378 0.024 0.357 0.997 DHA 57 0.384 0.024 0.370 DHA+ARA 61 0.366 0.022 0.335 Table 10 Red Blood Cell Phosphatidylethanolamine Fatty Acids Fatty Arithmetic Standard Regimen Pairwise Pairwise Time Acid Regimen n Hean Error Hedian p-value Comparison p-value Study Form Initiation 22:4n6 Control 52 7.290 0.182 7.402 0.875 DHA 57 7.431 0.186 7.638 DHA+ARA 61 7.456 0.167 7.270 Study Form Initiation 24:1 Control 52 0.100 0.028 0.041 0.068 DHA 57 0.059 0.009 0.031 DHA+ARA 61 0.072 0.010 0.047 Study Form Initiation 22:5n6 Control 52 1.757 0.083 1.782 0.555 DHA 57 1.809 0.070 1.857 DHA+ARA 61 1.851 0.075 1.775 Study Form Initiation 22:4n3 Control 52 0.001 0.001 0.000 0.257 DHA 57 0.001 0.001 0.000 DHA+ARA 61 0.005 0.002 0.000 I -P- Study Form Initiation 22:5n3 Control 52 1.496 0.109 1.308 0.195 DHA 57 1.375 0.109 0.988 DHA+ARA 61 1.380 0.097 1.041 Study Form Initiation 22:6n3 Control 52 6.119 0.200 6.381 0.375 DHA 57 6.444 0.185 6.468 DHA+ARA 61 6.407 0.220 6.579 Table 10 Red Blood Cell Phosphatidylethanolamine Fatty Acids Fatty Arithmetic Standard Regimen Pairwise Pairwise Time Acid Regimen n Mean Error Median p-value Comparison p-value Study Form Termination 12:0 Control 53 0.093 0.018 0.033 0.630 DHA 55 0.093 0.019 0.036 DHA+ARA 58 0.067 0.012 0.035 Study Form Termination 14:0 Control 53 0.360 0.031 0.279 0.782 DHA 55 0.380 0.039 0.265 DHA+ARA 58 0.348 0.030 0.256 Study Form Termination 14:1 Control 53 0.086 0.020 0.041 0.592 DHA 55 0.066 0.013 0.000 DHA+ARA 58 0.066 0.011 0.043 Study Form Termination 16:0 Control 53 19.326 0.673 17.617 0.560 DHA 55 19.062 0.614 17.556 DHA+ARA 58 18.357 0.467 17.568 I Study Form Termination 16:1 Control 53 0.511 0.034 0.476 0.604 DHA 55 0.579 0.045 0.509 I DHA+ARA 58 0.618 0.049 0.555 Study Form Termination 18:0 Control 53 9.614 0.266 9.406 0.024 Control vs DHA 0.130 DHA 55 9.173 0.208 8.818 Control vs DHA+ARA 0.006 DHA+ARA 58 8.961 0.242 8.697 DHA vs DHA+ARA 0.219 Study Form Termination 18:1 Control 53 14.763 0.437 14.695 0.333 DHA 55 15.177 0.299 14.927 DHA+ARA 58 14.814 0.330 14.499 Study Form Termination 18:2 Control 53 9.405 0.192 9.359 0.000 Control vs DHA 0.908 DHA 55 9.180 0.207 9.188 Control vs DHA+ARA 0.000 DHA+ARA 58 7.756 0.141 7.586 DHA vs DHA+ARA 0.000 Study Form Termination 18:3n6 Control 53 0.169 0.012 0.163 0.160 DHA 55 0.187 0.017 0.157 DHA+ARA 58 0.198 0.018 0.161 Table 10 Red Blood Cell Phosphatidylethanolamine Fatty Acids Fatty Arithmetic Standard Regimen Pairwise Pairwise Time Acid Regimen n Hean Error Median p-value Comparison p-value Study Form Termination 20:0 Control 53 0.404 0.044 0.278 0.146 DHA 55 0.336 0.037 0.208 DHA+ARA 58 0.288 0.029 0.208 Study Form Termination 18:3n3 Control 53 0.382 0.017 0.364 0.13- DHA 55 0.368 0.016 0.354 DHA+ARA 58 0.329 0.015 0.305 Study Form Termination 20:1 Control 53 0.553 0.029 0.526 0.164 DHA 55 0.579 0.028 0.537 DHA+ARA 58 0.507 0.025 0.483 Study Form Termination 18:4 Control 53 0.042 0.010 0.018 0.108 DHA 55 0.026 0.005 0.019 DHA+ARA 58 0.022 0.004 0.000 Study Form Termination 20:2n6 Control 53 0.754 0.029 0.765 0.068 DHA 55 0.774 0.030 0.750 DHA+ARA 58 0.654 0.026 0.663 Study Form Termination 20:3n6 Control 53 2.253 0.111 2.073 0.203 DHA 55 2.295 0.094 2.206 DHA+ARA 58 2.066 0.073 1.992 Study Form Termination 20:4n6 Control 53 24.279 0.527 25.132 0.000 Control vs DHA 0.119 DHA 55 23.464 0.520 24.038 Control vs DHA+ARA 0.000 DHA+ARA 58 26.760 0.437 27.372 DHA vs DHA+ARA 0.000 Study Form Termination 22:1 Control 53 0.149 0.019 0.122 0.229 DHA 55 0.176 0.016 0.169 DHA+ARA 58 0.146 0.012 0.130 Study Form Termination 20:5n3 Control 53 0.519 0.020 0.493 0.000 Control vs DHA 0.286 DHA 55 0.563 0.025 0.575 Control vs DHA+ARA 0.000 DHA+ARA 58 0.411 0.015 0.415 DHA vs DHA+ARA 0.000 Table 10 Red Blood Cell Phosphatidylethanolamine Fatty Acids Fatty Arithmetic Standard Regimen Pairwise Pairwise Time Acid Regimen n Mean Error Median p-value Comparison p-value Study Form Termination 22:4n6 Control 53 7.309 0.208 7.656 0.007 Control vs DHA 0.025 DHA 55 7.135 0.154 6.885 Control vs DHA+ARA 0.461 DHA+ARA 58 7.592 0.155 7.635 DHA vs DHA+ARA 0.002 Study Form Termination 24:1 Control 53 0.092 0.023 0.038 0.294 DHA 55 0.056 0.009 0.042 DHA+ARA 58 0.062 0.008 0.041 Study Form Termination 22:5n6 Control 53 1.444 0.064 1.423 0.010 Control vs DHA 0.003 DHA 55 1.231 0.034 1.213 Control vs DHA+ARA 0.255 DHA+ARA 58 1.347 0.040 1.330 DHA vs DHA+ARA 0.050 Study Form Termination 22:4n3 Control 53 0.000 0.000 0.000 0.137 DHA 55 0.004 0.002 0.000 DHA+ARA 58 0.004 0.002 0.000 I Study Form Termination 22:5n3 Control 53 2.694 0.110 2.839 0.003 Control vs DHA 0.004 I DHA 55 2.334 0.091 2.400 Control vs DHA+ARA 0.002 DHA+ARA 58 2.237 0.069 2.269 DHA vs DHA+ARA 0.943 Study Form Termination 22:6n3 Control 53 4.798 0.151 4.815 0.000 Control vs DHA 0.000 DHA 55 6.762 0.183 7.043 Control vs DHA+ARA 0.000 DHA+ARA 58 6.389 0.150 6.498 DHA vs DHA+ARA 0.027 Table 10 Red Blood Cell Phosphatidylethanolamine Fatty Acids Fatty Arithmetic Standard Regimen Pairwise Pairwise Time Acid Regimen n Hean Error Median p-value Comparison p-value Ueeks PCA 12:0 Control 37 0.053 0.019 0.024 0.587 DHA 32 0.054 0.016 0.019 DHA+ARA 38 0.047 0.014 0.018 HM 56 0.045 0.011 0.023 Weeks PCA 14 :0 Control 37 0.243 0.030 0.169 0.598 DHA 32 0.251 0.041 0.162 DHA+ARA 38 0.235 0.025 0.188 HM 56 0.230 0.016 0.210 Ueeks PCA 14 : 1 Control 37 0.080 0.017 0.037 0.092 DHA 32 0.055 0.017 0.000 DHA+ARA 38 0.078 0.019 0.044 HM 56 0.053 0.011 0.021 Ueeks PCA 16:0 Control 37 17.319 0.595 16.314 0.177 DHA 32 17.101 0.729 15.692 DHA+ARA 38 17.225 0.538 16.997 HM 56 18.138 0.395 17.607 Ueeks PCA 16: 1 Control 37 0.440 0.050 0.349 0.000 Control vs DHA 0.601 DHA 32 0.390 0.035 0.336 Control vs DHA+ARA 0.524 DHA+ARA 38 0.390 0.022 0.376 HM vs DHA 0.000 HM 56 0.596 0.027 0.562 HH vs DHA+ARA 0.000 Control vs HM 0.001 DHA vs DHA+ARA 0.928 Tabl e 10 Red Blood Cel l Phosphat i dyl ethanolami ne Fatty Ac ids Fatty Arithmetic Standard Re limen Pairwise Pairwise Ti e Acid Regimen n Mean Error Median p-value Comparison p-value Ueeks PCA 18:0 Control 37 7.935 0.327 7.174 0. ,000 Control vs DHA 0.347 DHA 32 7.962 0.293 7.552 Control vs DHA+ARA 0.483 DHA+ARA 38 7.443 0.270 7.173 HH vs DHA 0.020 HH 56 8.754 0.230 8.409 HH vs DHA+ARA 0.000 Control vs HH 0.001 DHA vs DHA+ARA 0.108 Ueeks PCA 18:1 Control 37 19.438 0.368 19.410 0. ,038 Control vs DHA 0.401 DHA 32 19.066 0.421 19.534 Control vs DHA+ARA 0.234 DHA+ARA 38 19.302 0.332 19.433 HM vs DHA 0.067 HM 56 18.469 0.278 18.141 HH vs DHA+ARA 0.118 Control vs HH 0.005 DHA vs DHA+ARA 0.758 Ueeks PCA 18:2 Control 37 9.328 0.261 9.267 0. .000 Control vs DHA 0.024 DHA 32 8.867 0.210 8.696 Control vs DHA+ARA 0.187 on DHA+ARA 38 9.257 0.216 8.840 HH vs DHA 0.000 HH 56 6.291 0.193 6.027 HH vs DHA+ARA 0.000 Control vs HM 0.000 DHA vs DHA+ARA 0.318 Ueeks PCA 18:3n6 Control 37 0.198 0.020 0.182 0 .050 Control vs DHA 0.879 DHA 32 0.219 0.031 0.171 Control vs DHA+ARA 0.590 DHA+ARA 38 0.188 0.021 0.158 HM vs DHA 0.029 HH 56 0.129 0.012 0.112 HH vs DHA+ARA 0.061 Control vs HH 0.014 DHA vs DHA+ARA 0.714 Ueeks PCA 20: 0 Control 37 0.263 0.058 0.146 0.728 DHA 32 0.262 0.042 0.145 DHA+ARA 38 0.212 0.037 0.125 HH 56 0.295 0.031 0.240 Table 10 Red Blood Cell Phosphatidylethanolamine Fatty Acids Fatty Arithmetic Standard Regimen Pairwise Pairwise Time Acid Regimen n Mean Error Median p-i /alue Comparison p-value Ueeks PCA 18:3n3 Control 37 0.291 0.025 0.225 0 .001 Control vs DHA 0.559 DHA 32 0.270 0.017 0.262 Control vs DHA+ARA 0.848 DHA+ARA 38 0.265 0.015 0.245 HH vs DHA 0.008 HH 56 0.226 0.020 0.169 HH vs DHA+ARA 0.002 Control vs HH 0.001 DHA vs DHA+ARA 0.689 Ueeks PCA 20:1 Control 37 0.715 0.031 0.648 0 .000 Control vs DHA 0.339 DHA 32 0.772 0.032 0.782 Control vs DHA+ARA 0.512 DHA+ARA 38 0.936 0.188 0.738 HH vs DHA 0.000 HH 56 0.533 0.024 0.492 HH vs DHA+ARA 0.000 Control vs HM 0.000 DHA vs DHA+ARA 0.115 Ueeks PCA 18:4 Control 37 0.017 0.005 0.003 0.057 DHA 32 0.017 0.005 0.000 DHA+ARA 38 0.023 0.006 0.000 HM 56 0.027 0.004 0.019 Ueeks PCA 20 :2n6 Control 37 0.672 0.035 0.698 0.000 Control vs DHA 0.543 DHA 32 0.668 0.026 0.684 Control vs DHA+ARA 0.532 DHA+ARA 38 0.715 0.032 0.689 HM vs DHA 0.000 HH 56 0.444 0.016 0.412 HH vs DHA+ARA 0.000 Control vs HH 0.000 DHA vs DHA+ARA 0.995 Ueeks PCA 20 :3n6 Control 37 2.138 0.099 1.999 0.012 Control vs DHA 0.896 DHA 32 2.165 0.100 2.045 Control vs DHA+ARA 0.935 DHA+ARA 38 2.172 0.114 2.132 HH vs DHA 0.015 HH 56 1.715 0.053 1.637 HM vs DHA+ARA 0.006 Control vs HM 0.007 DHA vs DHA+ARA 0.835 Table 10 Red Blood Cell Phosphatidylethanolamine Fatty Acids Fatty Arithmetic Standard Regimen Pairwise Pairwise Time Acid Regimen n Hean Error Median p-value Comparison p-value Ueeks PCA 20:4n6 Control 37 24.508 0.536 24.774 0.950 DHA 32 24.428 0.491 25.206 DHA+ARA 38 24.788 0.429 25.122 HM 56 24.625 0.384 25.189 Weeks PCA 22: 1 Control 37 0.168 0.016 0.172 0.121 DHA 32 0.189 0.022 0.188 DHA+ARA 38 0.154 0.022 0.133 HM 56 0.148 0.013 0.134 Weeks PCA 20:5n3 Control 37 0.382 0.026 0.368 0.497 32 I DHA 0.369 0.015 0.377 o DHA+ARA 38 0.347 0.011 0.347 HM 56 I 0.384 0.016 0.360 Ueeks PCA 22:4n6 ι Control 37 8.580 0.267 8.761 0.001 Control vs DHA 0.612 DHA 32 8.791 0.250 9.132 Control vs DHA+ARA 0.416 DHA+ARA 38 8.576 0.188 8.472 HH vs DHA 0.000 HM 56 7.727 0.203 7.618 HM vs DHA+ARA 0.013 Control vs HH 0.001 DHA vs DHA+ARA 0.199 Weeks PCA 24 : 1 Control 37 0.067 0.016 0.035 0.943 DHA 32 0.049 0.009 0.034 DHA+ARA 38 0.046 0.008 0.036 HM 56 0.062 0.016 0.027 Table 10 Red Blood Celt Phosphatidylethanolamine Fatty Acids Fatty Arithmetic Standard Regimen Pairwise Pairwise Time Acid Regimen n Hean Error Median p-value Comparison p-value Weeks PCA 22:5n6 Control 37 1.401 0.066 1.411 0.000 Control vs DHA 0.977 DHA 32 1 .353 0.057 1.414 Control vs DHA+ARA 0.997 DHA+ARA 38 1.364 0.054 1.359 HM vs DHA 0.000 HM 56 1 .883 0.056 1.889 HH VS DHA+ARA 0.000 Control vs HM 0.000 DHA vs DHA+ARA 0.975 Ueeks PCA 22:4n3 Control 37 0.000 0.000 0.000 1 .000 DHA 32 0.000 0.000 0.000 DHA+ARA 38 0.000 0.000 0.000 HM 56 0.001 0.001 0.000 Ueeks PCA 22:5n3 Control 37 2.567 0.092 2.681 0.000 Control vs DHA 0.884 I DHA 32 2.561 0.086 2.630 Control vs DHA+ARA 0.148 o DHA+ARA 38 2.436 0.066 2.443 HH vs DHA 0.000 HM 56 1.942 0.065 1.978 HH vs DHA+ARA 0.000 Control vs HM 0.000 DHA vs DHA+ARA 0.213 Ueeks PCA 22:6n3 Control 37 3.196 0.159 3.013 0.000 Control vs DHA 0.000 DHA 32 4.143 0.177 4.079 Control vs DHA+ARA 0.000 DHA+ARA 38 3.801 0.134 3.721 HM vs DHA 0.000 HM 56 7.283 0.201 7.341 HM VS DHA+ARA 0.000 Control vs HM 0.000 DHA vs DHA+ARA 0.281 Table 11 Preterm Infant Complications *The statistical test was based on a dichotomous response: present or absent. Table 12 Serious Adverse Events Reported During Study Formula Phase Table 13 Serious Adverse Events Reported During the Term Formula Phase Appendix 1 Listing of Weights Included in the Statistical Analyses Growth Rate Gender Regimen Subject Variable Wgt1 Wgt2 Ugt3 Wgt4 Wgt5 Wgt6 Wgt7 Wgt8 Wgt9 g/day Wgt_40 Wgt_48 Wgt_57 Hale Control 9698-0301 Weight (g) 1120 1240 1360 1590 1870 27.7 Age (weeks pea) 30.3 31.3 32.1 33.1 34.1 Hale Control 9698-0304 Weight (g) 1450 1630 1940 2180 36.1 3731 5752 6816 Age (weeks pea) 32.6 33.4 34.7 35.4 40.3 48.3 56.6 Hale Control 9699-0302 Weight (g) 958.0 1108 1251 1378 1659 23.9 3064 4993 6553 Age (weeks pea) 30.7 31.7 32.7 33.7 34.7 39.9 48.0 57.9 Halt Control 9699-0306 Weight (g) 1185 1261 1437 1647 1933 26.9 3575 4936 6014 Age (weeks pea) 31.0 32.0 33.0 34.0 35.0 40.3 48.3 57.1 Hale Control 9699-0308 Weight (g) 1600 1840 2752 43.3 3688 5504 6922 Age (weeks pea) 34.4 35.4 38.3 40.3 48.3 57.3 Hale Control 9700-0301 Weight (g) 1810 1855 2075 2330 2595 3120 36.2 3745 5080 6610 Age (weeks pea) 32.1 32.6 33.4 34.4 35.4 37.4 40.1 47.6 56.7 Hale Control 9701-0303 Weight (g) 1181 1298 1494 1785 2012 31.5 3070 3895 4965 Age (weeks pea) 32.4 33.4 34.4 35.4 36.3 41.6 48.6 57.6 Hale Control 9701-0304 Weight (g) 1412 1566 1851 2117 2318 34.1 3070 5445 7135 Age (weeks pea) 31.9 32.9 33.7 34.7 35.9 39.9 48.3 56.9 Hale Control 9702-0302 Weight (g) 1480 1775 2045 2240 2340 2570 33.8 3590 4840 6110 Age (weeks pea) 31.0 32.1 33.0 34.0 34.6 35.6 40.1 48.6 58.4 Hale Control 9703-0302 Weight (g) 1785 2040 2375 2685 2955 41.7 3620 5850 7470 Age (weeks pea) 33.3 34.6 35.6 36.4 37.4 39.7 48.6 57.3 Hale Control 9703-0304 Weight (g) 1475 1705 1920 2190 2425 34.2 3170 5240 6970 Age (weeks pea) 31.7 33.0 34.0 34.9 35.7 40.1 47.7 57.1 Hale Control 9703-0308 Weight (g) 1140 1230 1445 1665 1945 28.9 2520 4010 5030 Age (weeks pea) 31.7 32.6 33.7 34.7 35.7 39.7 48.4 56.9 Hale Control 9704-0303 Weight (g) 975.0 1205 1270 1450 1665 1760 2045 24.4 2150 3700 4950 Age (weeks pea) 32.3 33.4 34.4 35.4 36.3 37.3 38.3 39.3 48.3 57.4 * Four subjects had more the 9 weights used in growth rate calculation. A complete listing appears on the last page. Appendix 1 Listing of Weights Included in the Statistical Analyses Growth Rate Gender Regimen Subject Variable Wgtl Wgt2 Wgt3 Wgt4 Wgt5 Wgt6 Wgt7 Ugtβ Wgt9 g/ ay Wgt_40 Wgt_48 Ugt_57 Hale Control 9704-0305 Weight (g) 1315 1475 1640 1860 Age (weeks pea) 30.9 32.0 33.0 34.1 Hale Control 9705-0302 Weight (g) 1280 1389 1588 1786 2240 30.9 2540 4936 5646 Age (weeks pea) 33.0 34.0 35.0 36.0 37.4 39.6 47.4 56.4 Hate Control 9705-0304 Weight (g) 1270 1280 1570 1810 25.3 3291 5816 7490 Age (weeks pea) 31.3 32.3 33.3 34.6 39.7 47.7 56.7 Hale Control 9706-0302 Weight (g) 1645 1865 2130 2435 37.1 2800 4660 6170 Age (weeks pea) 35.7 36.6 37.7 38.7 40.1 48.7 56.7 Hale Control 9706-0303 Weight (g) 1875 1984 2135 2185 2465 22.2 3050 4550 6675 Age (weeks pea) 33.7 34.7 35.6 36.4 37.3 41.0 48.6 56.9 Hale Control 9706-0308 Ueight (g) 1655 1734 2005 2495 46.9 3835 5155 6090 Age (weeks pea) 32.9 33.1 34.0 35.4 40.6 48.0 56.3 Hale Control 9707-0302 Weight (g) 1544 1820 2215 2450 2460 32.8 2930 3795 5185 Age (weeks pea) 31.6 32.9 34.4 35.4 35.7 40.1 47.7 56.6 Hale Control 9707-0303 Weight (g) 1415 1600 1850 2195 2310 32.7 2530 4235 6530 Age (weeks pea) 33.1 34.1 35.1 36.6 37.1 39.7 47.7 57.1 Hale Control 9707-0309 Weight (g) 1046 1442 1644 1910 30.7 2965 4465 Age (weeks pea) 30.9 32.7 33.7 34.9 39.9 48.0 Hate Control 9708-0303 Weight (g) 1730 1960 2205 2520 37.4 3680 5470 7330 Age (weeks pea) 32.7 33.7 34.7 35.7 40.1 48.1 57.0 Hale Control 9709-0302 Weight (g) 1090 1440 1660 1910 2040 30.8 3845 5700 6775 Age (weeks pea) 29.9 31.7 32.7 33.7 34.3 39.9 48.0 56.7 Hale Control 9712-0301* Weight (g) 1245 1221 1245 1291 1294 1330 1369 1402 1433 26.1 Age (weeks pea) 31.6 31.7 31.9 32.0 32.1 32.3 32.4 32.6 32.7 Hale Control 9712-0302 Weight (g) 1292 1345 1456 1670 1835 1985 21.0 2160 3300 3980 Age (weeks pea) 33.1 34.1 35.1 36.1 37.1 38.1 40.1 47.7 57.3 * Four subjects had more the 9 weights used in growth rate calculation. A complete listing appears on the last page. Appendix 1 Listing of Weights Included in the Statistical Analyses Growth Rate Gender Regimen Subject Variable Wgt1 Wgt2 Wgt3 Wgt4 Ugt5 Wgt6 Wgt7 Wgt8 Wgt9 g/day Wgt_40 Wgt_48 Wgt_57 Hate Control 9743- 0301 Weight (g) 1520 1570 1670 1720 10.0 2260 4535 Age (weeks pea) 34.1 35.0 36.0 37.1 41.0 50.0 Hale Control 9746- 0301 Weight (g) 2065 2465 2760 3085 3085 48.9 3085 4795 6695 Age (weeks pea) 37.6 38.9 39.7 40.6 40.6 40.6 47.6 57.6 Hale DHA 9698- 0302 Weight (g) 1640 1860 3170 47.5 3170 5206 7036 Age (weeks pea) 35.1 36.1 39.9 39.9 47.9 57.1 Hale DHA 9698- 0306 Weight (g) 1620 1830 2090 2575 28.3 2575 4334 6022 Age (weeks pea) 35.1 36.3 37.3 40.0 40.0 48.0 57.0 Hale DHA 9699- 0301 Weight (g) 1018 1207 1360 1617 27.9 3121 5192 6752 Age (weeks pea) 31.3 32.3 33.3 34.3 39.9 48.0 57.9 Hale DHA 9699- ■ 0303 Weight (g) 1258 1435 1631 1882 2724 48.3 2724 4341 5674 Age (weeks pea) 32.4 33.4 34.4 35.4 36.4 40.1 48.1 57.0 Hale DHA 9699* • 0307 Weight (g) 1182 1358 1484 1666 22.5 1986 3206 4511 Age (weeks pea) 34.7 35.7 36.7 37.7 40.0 48.0 57.0 Hale DHA 9700* -0303 Weight (g) 1830 1980 2450 3045 45.4 3585 5420 7035 Age (weeks pea) 33.9 34.4 35.9 37.7 39.6 47.4 56.7 Hale DHA 9701- -0301 Weight (g) 1098 1234 1365 1689 1902 2019 2104 2276 2288 20.4 2805 3405 4660 Age (weeks pea) 29.6 30.6 31.6 33.4 34.6 35.6 36.4 37.4 38.6 40.4 47.6 57.0 Hale DHA 9701 -0305 Weight (g) 1621 1829 1880 2253 2582 34.7 3660 Age (weeks pea) 31.7 33.1 33.7 34.7 35.7 39.7 Hale DHA 9703 -0303 Weight (g) 1775 2030 2285 2595 2780 38.2 3080 3940 5260 Age (weeks pea) 33.3 34.1 35.1 36.0 37.1 39.9 48.0 56.9 Hale DHA 9703 -0306 Weight (g) 1725 1870 2180 41.7 Age (weeks pea) 33.4 34.0 35.0 Hale DHA 9703 -0307 Weight (g) 1525 1725 2020 2390 37.6 3120 4410 5600 Age (weeks pea) 32.7 33.7 34.9 36.0 40.7 47.9 56.9 Four subjects had more the 9 weights used in growth rate calculation. A complete listing appears on the last page. Appendix 1 Listing of Weights Included in the Statistical Analyses Growth Rate Gender Regimen Subject Variable Wgtl Wgt2 Wgt3 Wgt4 Wgt5 Wgt6 Wgt7 Wgt8 Ugt9 g/day Wgt_40 Wgt_48 Wgt_57 Hale DHA 9704- 0304 Weight (g) 1380 1570 1730 1960 2140 29.3 2880 3900 4300 Age (weeks pea) 32.1 33.1 34.1 35.0 35.9 40.3 48.3 57.3 Hale DHA 9704- 0306 Weight (g) 1320 1370 1550 1760 2020 2170 25.6 3750 4800 Age (weeks pea) 30.7 31.7 32.7 33.7 34.7 35.9 48.0 57.0 Hale DHA 9705- 0303 Weight (g) 1380 1446 1616 1843 2330 30.8 2370 4170 5787 Age (weeks pea) 33.0 34.0 35.0 36.0 37.4 39.6 47.4 56.4 Hale DHA 9705- 0305 Weight (g) 1490 1770 1980 2240 36.7 3291 Age (weeks pea) 31.1 32.1 33.1 34.0 39.6 Hale DHA 9706- 0304 Weight (g) 1490 1655 1915 2260 36.8 3335 5265 6900 Age (weeks pea) 33.0 33.7 34.7 36.0 40.0 48.1 57.3 Hate DHA 9706- • 0306 Weight (g) 1604 1908 2160 42.8 3310 4205 5600 Age (weeks pea) 34.4 35.4 36.3 41.4 47.6 56.9 Hale DHA 9707 * • 0001 Weight (g) 1305 1429 17.7 Age (weeks pea) 31.0 32.0 Hale DHA 9707- • 0304 Weight (g) 1555 1740 1990 2400 2570 36.9 3280 5115 6755 Age (weeks pea) 32.0 33.0 34.0 35.4 36.0 39.9 48.0 57.6 Hale DHA 9707 -0306 Weight (g) 1728 2040 2260 3050 3050 43.2 3050 5100 7150 Age (weeks pea) 36.1 37.3 38.1 40.6 40.6 40.6 48.6 57.6 Hale DHA 970 -0307* Weight (g) 1649 1675 1699 1732 1778 1811 1858 1882 1938 39.6 Age (weeks pea) 32.4 32.6 32.7 32.9 33.0 33.1 33.3 33.4 33.6 Hale DHA 9707 -1308 Weight (g) 1780 2045 3004 3004 36.7 3004 4420 6090 Age (weeks pea) 34.4 35.7 39.3 39.3 39.3 47.3 57.7 Hale DHA 9707 -2308 Weight (g) 1651 1923 2850 2850 35.8 2850 4375 5930 Age (weeks pea) 34.4 35.7 39.3 39.3 39.3 47.3 57.7 Hale DHA 9708 -0302 Weight (g) 1485 1740 2500 39.2 3873 6256 Age (weeks pea) 33.3 34.3 37.0 42.9 57.3 Four subjects had more the 9 weights used in growth rate calculation. A complete listing appears on the last page. Appendix 1 Listing of Weights Included in the Statistical Analyses Growth Rate Gender Regimen Subject Variable Wgt1 Wgt2 Wgt3 Wgt4 Wgt5 Wgt6 Ugt7 Wgt8 Wgt9 g/day Wgt_40 Wgt_48 Ugt 57 Hale DHA 9709-0301 Weight (g) 1490 1740 2000 2400 2800 44.4 3150 5080 6750 Age (ueeks pea) 32.4 33.4 34.4 35.4 36.7 39.4 47.4 56.4 Hale DHA 9709-0304 Weight (g) 1470 1520 7.1 Age (weeks pea) 34.4 35.4 Hale DHA 9712-0304 Weight (g) 1545 1800 1985 2160 2550 30.5 3160 5200 7300 Age (weeks pea) 33.0 34.0 35.0 36.0 37.6 40.3 48.1 57.1 Hale DHA 9712-0306 Weight (g) 1240 1435 1695 1945 33.9 3040 4680 5860 Age (weeks pea) 31.5 32.5 33.5 34.5 39.6 48.6 57.6 Hale DHA 9743-0303 Weight (g) 1700 1810 2100 2300 31.1 3100 5500 Age (weeks pea) 32.9 33.9 34.9 35.7 40.6 48.6 Hale DHA 9743-0304 Weight (g) 1530 1880 2160 2375 2440 32.2 3628 5840 Age (weeks pea) 32.3 34.0 35.0 36.0 36.4 38.1 50.6 Hale DHA+ARA 9698-0305 Weight (g) 1120 1340 1550 20.9 2440 5525 6646 Age (weeks pea) 30.7 32.6 33.6 37.4 47.6 56.6 Male DHA+ARA 9698-0308 Weight (g) 1410 1690 1870 2120 32.0 3553 6007 7937 Age (weeks pea) 31.1 32.4 33.3 34.3 40.3 47.6 57.3 Hale DHA+ARA 9699-0304 Weight (g) 1499 1689 1950 2355 29.8 2355 3404 4993 Age (weeks pea) 36.1 37.1 38.1 40.3 40.3 48.0 57.1 Hale DHA+ARA 9699-0305 Weight (g) 1056 1134 1290 1490 17.2 2610 4256 5050 Age (weeks pea) 32.0 33.0 34.0 35.7 40.6 48.7 57.6 Hale DHA+ARA 9700-0302 Weight (g) 1635 1880 2235 2570 2735 40.7 3255 5540 7380 Age (weeks pea) 33.9 34.7 35.9 36.9 37.9 39.7 47.7 56.7 Hale DHA+ARA 9701-0302 Weight (g) 1442 1686 2045 2835 48.9 3240 5055 6600 Age (weeks pea) 33.6 34.6 35.6 37.7 39.7 46.7 56.7 Hale DHA+ARA 9701-0306 Weight (g) 1587 2037 2245 2460 2756 3072 3228 41.4 3960 5200 Age (weeks pea) 32.3 33.4 34.4 35.3 36.3 37.3 37.7 42.3 48.4 Four subjects had more the 9 weights used in growth rate calculation. A complete listing appears on the last page. Appendix 1 Listing of Weights Included in the Statistical Analyses Growth Rate Gender Regimen Subject Variable Wgt1 Wgt2 Wgt3 Wgt4 Ugt5 Wgtό Wgt7 Wgtβ Wgt9 g/day Wgt_40 Wgt_48 Wgt_5; Hale DHA+ARA 9701-0307 Weight (g) 1397 1710 1919 2932 42.5 3445 5930 7475 Age (weeks pea) 33.3 34.3 35.1 38.4 40.6 48.6 57.4 Hale DHA+ARA 9702-0301 Weight (g) 1670 1865 2160 2660 36.0 3780 5250 Age (weeks pea) 32.0 33.0 34.0 36.0 40.6 47.6 Hale DHA+ARA 9702-0303 Weight <g) 1650 1905 2660 40.7 3500 5160 6520 Age (weeks pea) 32.9 33.9 36.4 40.0 48.0 56.4 Hale DHA+ARA 9703-0301 Weight (g) 1255 1460 1745 2055 2415 42.3 4350 6020 6720 Age (weeks pea) 29.4 30.4 31.3 32.3 33.4 40.4 47.4 56.6 Hale DHA+ARA 9703-0305 Weight (g) 1440 1635 1830 2115 2390 2590 34.1 3170 4330 5630 Age (weeks pea) 32.0 33.0 34.0 35.0 36.1 36.9 40.0 47.9 56.7 Hate DHA+ARA 9704-0301 Weight (g) 1110 1270 1490 1740 2050 35.1 3220 5460 7050 Age (weeks pea) 30.6 31.6 32.4 33.4 34.4 39.9 47.7 56.7 Hale DHA+ARA 9704-0302 Weight (g) 1080 1230 1370 1520 1680 1840 22.2 2570 6540 8050 Age (weeks pea) 32.0 33.0 34.0 34.9 36.0 36.9 40.0 48.1 57.4 Hale DHA+ARA 9705-0301 Weight (g) 1300 1440 1620 1870 27.0 2979 4400 5873 Age (weeks pea) 32.7 33.7 34.7 35.7 40.1 48.1 58.0 Hale DHA+ARA 9705-0306 Weight (g) 1320 1490 1700 2020 2300 32.7 3631 5447 6809 Age (weeks pea) 31.4 32.4 33.4 34.4 35.9 39.9 47.9 56.9 Hale DHA+ARA 9705-0307 Weight (g) 1480 1650 1810 2240 36.4 3007 5589 6596 Age (weeks pea) 34.4 35.4 36.1 37.4 39.9 48.4 56.7 Hale DHA+ARA 9706-0305 Weight (g) 1330 1455 1660 1930 31.4 2695 4820 6225 Age (weeks pea) 33.9 34.4 35.4 36.6 39.9 48.1 58.1 Hale DHA+ARA 9706-0307 Weight (g) 1355 1585 1825 2270 40.0 3585 5955 6925 Age (weeks pea) 31.9 33.0 33.9 35.1 40.4 49.1 57.6 Hale DHA+ARA 9706-0309 Weight (g) 1620 1910 2150 40.3 3460 5255 5775 Age (weeks pea) 34.1 35.3 36.0 40.9 48.7 57.4 Four subjects had more the 9 weights used in growth rate calculation. A complete listing appears on the last page. Appendix 1 Listing of Weights Included in the Statistical Analyses Growth Rate Gender Regimen Subject Variable Wgt1 Wgt2 Wgt3 Wgt4 Wgt5 Wgt6 Wgt7 Wgt8 Wgt9 g/day Wgt_40 Wgt_48 Wgt_5 Hale DHA+ARA 9707-0301 Weight (g) 1553 1980 2280 2720 41.5 3395 4950 6285 Age (weeks pea) 32.6 34.3 35.3 36.6 40.1 47.9 56.9 Hale DHA+ARA 9707-0305 Weight (g) 1755 1990 2245 2505 2770 37.4 Age (weeks pea) 33.9 34.7 35.7 36.7 37.7 Hale DHA+ARA 9707-0310 Weight (g) 1620 1828 2140 3195 44.8 3585 5170 6725 Age (weeks pea) 32.7 33.7 34.7 37.9 39.7 47.9 56.3 Hale DHA+ARA 9708-0301 Weight (g) 1640 1880 2200 2420 38.0 3730 4835 6185 Age (weeks pea) 32.7 33.7 34.7 35.7 40.1 47.9 57.0 Hale DHA+ARA 9708-0304 Weight (g) 1680 2180 55.6 Age (weeks pea) 34.6 35.9 Hale DHA+ARA 9709-0303 Weight (g) 1470 1810 48.6 Age (weeks pea) 32.6 33.6 Hale DHA+ARA 9709-0305 Weight (g) 1410 1655 1900 2160 35.6 2630 4570 5520 Age (weeks pea) 34.4 35.4 36.4 37.4 39.7 47.7 57.1 Hale DHA+ARA 9712-0303 Weight (g) 1180 1210 1450 1590 20.9 2520 3500 5010 Age (weeks pea) 31.4 32.3 33.4 34.4 40.4 47.4 56.4 Hale DHA+ARA 9712-0305 Weight (g) 1325 1505 1785 2010 2300 34.1 3030 4350 5510 Age (weeks pea) 31.5 32.5 33.5 34.5 35.6 39.6 48.6 57.6 Hale DHA+ARA 9723-0301 Weight (g) 1630 1728 1961 2214 28.4 3104 5986 Age (weeks pea) 33.9 34.9 35.9 36.9 40.3 58.9 Hale HH 9698-0601 3518 5497 6582 40.0 48.3 56.9 Hale HH 9698-0602 3177 5220 6355 40.0 48.1 57.0 Hale HH 9698-0603 3858 5447 6454 40.0 48.0 57.0 * Four subjects had more the 9 weights used in growth rate calculation. A complete listing appears on the last page. Appendix 1 Listing of Weights Included in the Statistical Analyses Growth Rate Gender Regimen Subject Variable Wgt1 Wgt2 Wgt3 Wgt4 Wgt5 Wgt6 Wgt7 Wgt8 Wgt9 g/day Wgt_40 Wgt_48 Wgt_57 Hale HH 9698-0604 4355 5092 6383 40.0 48.0 57.0 Hale HH 9698-0605 3433 4979 6426 40.0 48.1 57.1 Hale HH 9699-0501 3915 6639 7773 40.0 48.3 57.4 Hale HH 9699-0502 3802 5787 7178 40.0 48.4 57.4 Hale HH 9701-0601 3317 5555 7070 40.0 47.9 56.4 Hale HH 9701-0602 3487 5833 8070 Hale HH 9701-0603 Hale HH 9701-0604 3600 5215 6285 40.0 47.9 56.9 Male HH 9701-0605 3402 5575 7210 40.0 47.6 57.6 Hate HH 9701-0606 3090 4485 5445 40.0 47.7 56.7 Hale HH 9702-0601 3480 5780 6530 40.0 48.6 56.6 Male HM 9702-0602 3165 5060 6660 40.0 48.3 57.1 Hale HM 9703-0502 2670 5420 7220 40.0 48.3 57.1 * Four subjects had more the 9 weights used in growth rate calculation. A complete listing appears on the last page. Appendix 1 Listing of Weights Included in the Statistical Analyses Growth Rate Gender Regimen Subject Variable Wgt1 Wgt2 Wgt3 Wgt4 Wgt5 Wgt6 Wgt7 Wgtβ Wgt9 g/day Wgt_40 Wgt_48 Wgt_57 Male HH 9703-0503 4100 6740 8330 40.0 47.4 56.4 Hate HH 9703-0504 3435 6000 7930 40.0 48.1 57.1 Hale HM 9704-0502 3285 5220 6560 40.0 48.1 56.6 Hale HH 9704-0503 3400 5200 6725 40.0 48.7 56.9 Hate HM 9705-0601 3200 5617 6752 40.0 48.3 57.3 Hale HH 9705-0602 3860 6227 Male HH 9706-0601 3152 5105 6545 40.0 49.0 57.0 Male HM 9706-0602 3557 5175 7315 40.0 47.4 57.7 Male HH 9706-0603 3192 5070 6970 40.0 47.9 56.7 Hale HM 9706-0604 3461 4225 5525 40.0 48.0 57.1 Hale HM 9706-0605 3870 6220 7660 40.0 48.1 56.4 Male HH 9706-0606 4315 5975 6720 40.0 48.3 56.6 Male HM 9707-0601 3263 4730 5825 40.0 48.1 57.0 * Four subjects had more the 9 weights used in growth rate calculation. A complete listing appears on the last page. Appendix 1 Listing of Weights Included in the Statistical Analyses Growth Rate Gender Regimen Subject Variable Wgt1 Wgt2 Wgt3 Wgt4 Wgt5 Wgt6 Wgt7 Wgt8 Wgt9 g/day Wgt_40 Wgt_48 Wgt 57 Hale HM 9707-0602 3206 4515 6220 40.0 48.1 57.7 Male HH 9707-0603 4256 6930 8810 40.0 48.0 57.0 Hale HM 9707-0604 3419 5460 6130 40.0 48.0 56.7 Hale HM 9707-0605 3433 40.0 Hale HH 9707-0606 3603 5825 40.0 48.4 Hale HM 9707-0607 3569 5410 6870 Hale HM 9707-0608 Hale HM 9707-0609 3348 40.0 Hale HM 9708-0601 3064 5220 6595 40.0 47.6 56.4 Hale HH 9708-0602 4085 40.0 Hale HM 9708-0603 3319 5135 6327 40.0 48.4 57.1 Hale HH 9708-0604 3291 40.0 Hale HM 9708-0605 3796 40.0 * Four subjects had more the 9 weights used in growth rate calculation. A complete listing appears on the last page. Appendi 1 Listing of Weights Included in the Statistical Analyses Growth Rate Gender Regimen Subject Variable Wgt1 Wgt2 Wgt3 Wgt4 Wgt5 Wgt6 Wgt7 Wgt8 Wgt9 g/day Wgt_40 Wgt_48 Wgt_57 Hale HH 9708-0606 4020 4645 5405 40.0 48.4 57.1 Male HM 9708-0607 3333 4043 5180 40.0 47.9 56.7 Hale HH 9709-0505 3400 40.0 Female Control 9698-0003* Weight (g) 1020 1050 1070 1080 1080 1060 1080 1070 5.6 Age (weeks pea) 31.1 31.3 31.4 31.6 31.7 31.9 32.0 32.1 Female Control 9699-0001 Weight (g) 1464 1672 1862 2000 2145 24.1 2610 4369 5220 Age (weeks pea) 32.7 33.7 34.7 35.7 36.7 39.7 47.9 56.9 Female Control 9699-0003 Weight (g) 1473 1629 1860 2497 37.3 2780 4596 5816 I Age (weeks pea) 34.0 35.0 36.0 38.0 40.0 48.0 57.0 σ αo I Female Control 9701-0003 Weight (g) 1480 1633 1903 1975 2292 29.1 2675 4165 5200 Age (weeks pea) 34.6 35.6 36.6 37.3 38.6 40.6 48.6 55.6 Female Control 9701-0005 Ueight (g) 1174 1366 1555 1745 1976 28.3 3175 5140 6280 Age (weeks pea) 30.7 31.7 32.7 33.7 34.7 39.7 48.4 56.4 Female Control 9701-0008 Weight (g) 1391 1569 1898 2198 2406 41.1 2980 4425 5815 Age (weeks pea) 34.3 35.3 36.4 37.3 37.9 40.4 47.4 56.4 Female Control 9701-0011 Weight (g) 1050 1254 1492 1756 2044 36.6 2870 4420 5505 Age (weeks pea) 30.6 31.4 32.4 33.4 34.4 39.7 48.6 57.4 Female Control 9702-0002 Weight (g) 1222 1371 1570 1750 1995 2390 29.4 3380 4900 Age (weeks pea) 31.7 32.7 34.1 35.1 36.0 37.1 40.4 47.6 Female Control 9702-0004 Weight (g) 1454 1555 1840 2530 31.6 3600 5160 6900 Age (weeks pea) 31.0 31.9 33.1 36.0 39.9 47.7 56.7 Female Control 9702-0010 Weight (g) 1775 2065 2410 2645 42.2 3060 4820 6690 Age (weeks pea) 34.0 35.0 36.0 37.0 39.9 48.3 57.6 * Four subjects had more the 9 weights used in growth rate calculation. A complete listing appears on the last page. Appendix 1 Listing of Weights Included in the Statistical Analyses Growth Rate Gender Regimen Subject Variable Wgt1 Wgt2 Wgt3 Wgt4 Wgt5 Wgt6 Wgt7 Wgt8 Wgt9 g/day Wgt_40 Wgt_48 Wgt : Female Control 9703-0002 Weight (g) 1170 1250 1390 1570 1825 2130 26.4 3210 4750 Age (weeks pea) 29.1 30.4 31.3 32.4 33.4 34.3 39.6 47.4 Female Control 9703-0005 Weight (g) 1420 1590 1765 1900 2220 29.5 2610 4330 5640 Age (weeks pea) 31.4 32.3 33.3 33.9 35.3 37.3 46.0 55.0 Female Control 9703-0008 Weight (g) 1495 1715 2095 2445 2685 48.3 3360 4780 6410 Age (weeks pea) 33.0 34.0 35.0 36.0 36.6 40.1 47.7 56.1 Female Control 9705-0004 Weight (g) 1120 1290 1490 1660 28.3 2722 4085 5646 Age (weeks pea) 31.3 32.3 33.3 34.0 39.7 46.6 55.0 Female Control 9706-0003 Weight (g) 1515 1673 1965 2330 37.9 Age (weeks pea) 35.1 36.3 37.1 38.3 Female Control 9706-0005 Weight (g) 1485 1610 1805 2150 31.7 2740 4165 5305 I Age (weeks pea) 33.0 33.7 34.7 36.0 40.0 48.1 57.3 a I Female Control 9706-0009 Weight (g) 1525 1620 1960 31.6 3640 5495 7225 Age (weeks pea) 32.3 32.9 34.3 40.3 47.6 53.4 Female Control 9706-0010 Weight (g) 1905 2185 56.0 3655 5390 6535 Age (weeks pea) 34.3 35.0 40.0 48.4 56.7 Female Control 9706-0013 Weight (g) 1185 1270 1585 1810 31.1 2680 3800 Age (weeks pea) 31.6 32.4 33.6 34.6 40.1 48.4 Female Control 9706-0016 Weight (g) 1510 1765 1935 32.6 3320 4535 5297 Age (weeks pea) 32.0 33.1 33.9 40.7 48.7 56.6 Female Control 9707-0003 Weight (g) 1465 1505 1655 2010 2325 2765 30.2 3110 4125 4995 Age (weeks pea) 32.0 32.6 33.6 35.3 36.4 38.3 40.1 48.1 57.1 Female Control 9707-0006 Weight (g) 1866 3430 3430 41.2 3430 5385 7250 Age (weeks pea) 34.6 40.0 40.0 40.0 48.9 57.3 Female Control 9707-1006 Weight (g) 1815 3330 3330 39.9 3330 5490 6920 Age (weeks pea) 34.6 40.0 40.0 40.0 48.9 57.3 * Four subjects had more the 9 weights used in growth rate calculation. A complete listing appears on the last page. Appendix 1 Listing of Weights Included in the Statistical Analyses Growth Rate Gender Regimen Subject Variable Wgt1 Wgt2 Wgt3 Wgt4 Wgt5 Wgt6 Wgt7 Wgtβ Wgt9 g/day Wgt_40 Wgt_48 Wgt 57 Female Control 9708-0001 Weight (g) 1410 1600 1850 2050 27.2 2910 4734 Age (weeks pea) 33.4 34.4 35.4 36.9 40.6 48.4 Female Control 9708-0003 Weight (g) 940.0 970.0 4.3 Age (weeks pea) 30.0 31.0 Female Control 9708-0008 Weight (g) 1380 1605 1860 2180 33.1 2582 4110 5361 Age (weeks pea) 32.9 33.7 34.9 36.3 39.3 47.4 57.1 Female Control 9709-0002 Weight (g) 1980 2225 2400 30.0 Age (weeks pea) 32.7 33.7 34.7 Female Control 9709-0005 Weight (g) 1175 1425 1665 1945 2200 32.3 2975 4700 5900 Age (weeks pea) 31.9 33.3 34.6 35.6 36.3 39.6 48.4 56.7 Female Control 9712-0005 Weight (g) 972.0 1145 1290 1490 1695 25.6 2930 4450 5880 Age (weeks pea) 29.1 30.1 31.1 32.1 33.1 40.3 47.6 57.1 Female Control 9712-0006 Weight (g) 1203 1358 1585 1790 28.4 3030 4560 6230 Age (weeks pea) 31.9 32.9 33.9 34.9 39.7 48.0 57.0 Female Control 9743-0003 Weight (g) 1300 1520 1740 1890 24.0 4000 5160 Age (weeks pea) 31.6 33.4 34.1 35.1 48.4 57.4 Female Control 9746-0001 Weight (g) 1420 1740 2075 2320 2625 42.7 3170 4145 5192 Age (weeks pea) 32.6 33.6 34.6 35.6 36.6 39.7 47.6 56.6 Female DHA 9698-0004 Weight (g) 1410 1650 1890 2140 34.7 3787 4795 6291 Age (weeks pea) 30.1 31.1 32.1 33.1 40.0 48.0 57.0 Female DHA 9698-0006 Weight (g) 1110 1240 1420 1720 28.7 Age (weeks pea) 30.7 31.7 32.7 33.7 Female DHA 9698-0009 Weight (g) 1205 1310 1520 1630 2020 25.9 2891 3979 5121 Age (weeks pea) 30.3 31.4 32.4 33.1 34.9 40.0 48.0 57.0 Female DHA 9698-0307 Weight (g) 1790 2110 2450 29.7 3135 5185 6695 Age (weeks pea) 34.4 35.7 37.6 39.4 47.4 56.4 * Four subjects had more the 9 weights used in growth rate calculation. A complete listing appears on the last page. Appendix 1 Listing of Weights Included in the Statistical Analyses Growth Rate Gender Regimen Subject Variable Wgt1 Wgt2 Wgt3 Wgt4 Wgt5 Ugt6 Wgt7 Wgtβ Ugt9 g/day Wgt_40 Wgt_48 Wgt_57 Female DHA 9699-0002 Weight (g) 1313 1477 1669 1929 2380 36.9 3177 5787 7093 Age (weeks pea) 32.9 33.9 34.9 35.9 36.9 39.7 47.7 56.7 Female DHA 9700-0001 Weight (g) 1580 1820 2050 2295 2500 34.5 3210 5110 6300 Age (weeks pea) 32.4 33.4 34.3 35.3 36.3 40.1 48.1 57.1 Female DHA 9701-0001 Weight (g) 1300 1356 1586 1924 2125 34.2 2910 4325 5625 Age (weeks pea) 33.0 34.0 35.0 36.0 36.6 39.6 48.0 57.0 Female DHA 9701-0004 Weight (g) 1108 1261 1441 1671 1897 28.4 3020 4855 6040 Age (weeks pea) 30.7 31.7 32.7 33.7 34.7 39.7 48.4 56.4 Fe aIe DHA 9701-0012 Weight (g) 1674 1928 2151 2311 2685 2685 30.1 2685 Age (weeks pea) 34.9 35.9 36.9 37.6 39.6 39.6 39.6 Fe a I e DHA 9701-0014 Weight (g) 1422 1631 1858 2455 37.2 2970 4605 5140 Age (weeks pea) 33.9 34.9 35.9 37.9 39.9 47.7 56.9 Female DHA 9702-0001 Weight (g) 1780 2115 2390 3000 35.8 3850 5610 6600 Age (weeks pea) 31.6 32.9 33.9 36.4 40.0 49.6 57.0 Female DHA 9702-0006 Weight (g) 1850 2005 2650 2650 27.3 2650 4450 6020 Age (weeks pea) 35.4 36.1 39.6 39.6 39.6 48.4 56.4 Female DHA 9702-0007 Weight (g) 1285 1459 1780 1965 2035 29.6 Age (weeks pea) 31.1 32.1 33.6 34.4 34.9 Female DHA 9702-0008 Weight (g) 1605 1930 3540 3540 51.3 3540 5920 7820 Age (weeks pea) 34.1 35.1 39.6 39.6 39.6 47.6 57.1 Female DHA 9703-0003 Weight (g) 1255 1355 1535 1845 2150 34.8 2430 4130 5010 Age (weeks pea) 34.4 35.1 36.1 37.1 38.1 39.4 48.0 56.1 Female DHA 9703-0004 Weight (g) 1170 1340 1550 1795 2225 33.9 2870 4610 6490 Age (weeks pea) 32.6 33.3 34.3 35.3 37.0 39.4 48.1 57.1 Female DHA 9703-0009 Weight (g) 1570 1830 2095 2395 2655 34.6 3160 4480 5570 Age (weeks pea) 33.3 34.3 35.1 36.3 37.9 40.4 48.4 58.0 Four subjects had more the 9 weights used in growth rate calculation. A complete listing appears on the last page. Appendix 1 Listing of Weights Included in the Statistical Analyses Growth Rate Gender Regimen Subject Variable Wgt1 Wgt2 Wgt3 Wgt4 Wgt5 Wgt6 Wgt7 Wgtβ Ugt9 g/day Wgt_4Q Wgt_48 Wgt 57 Female DHA 9704-0004 Weight (g) 1440 1670 1740 30.5 3100 5830 8630 Age (weeks pea) 33.6 34.6 35.0 40.0 48.0 57.0 Female DHA 9704-0005 Weight (g) 1050 1310 1490 1700 1890 30.0 3360 4860 6100 Age (weeks pea) 29.7 30.9 31.7 32.7 33.7 39.6 48.0 57.0 Female DHA 9705-0001 Weight (g) 1220 1370 1590 1880 2098 31.9 3092 4795 5986 Age (weeks pea) 32.7 33.6 34.7 35.7 36.7 40.1 48.1 57.1 Female DHA 9706-0006 Weight (g) 1270 1405 1630 1930 31.7 2705 4145 5320 Age (weeks pea) 33.0 33.7 34.7 36.0 40.0 48.1 57.3 Female DHA 9706-0008 Weight (g) 990.0 1188 1345 1485 23.0 2120 Age (weeks pea) 33.4 34.6 35.7 36.4 39.9 emale DHA 9706-0012 Weight (g) 1610 1830 2130 2280 32.5 3530 4790 Age (weeks pea) 31.6 32.4 33.6 34.6 40.1 48.4 Female DHA 9706-0014 Weight (g) 1080 1170 1395 1560 1804 26.2 3295 5600 7675 Age (weeks pea) 31.3 32.6 33.4 34.4 35.3 40.6 49.4 58.0 emale DHA 9707-0004 Weight (g) 1635 1771 2850 38.1 3045 4595 5765 Age (weeks pea) 34.0 35.0 38.7 40.0 48.0 57.0 Female DHA 9707-0308 Weight (g) 2005 3440 3440 42.2 3440 4800 6360 Age (weeks pea) 34.4 39.3 39.3 39.3 47.3 57.7 Female DHA 9708-0004 Weight (g) 1460 1665 1955 2280 2485 38.1 Age (weeks pea) 32.6 33.6 34.6 35.6 36.6 Female DHA 9708-0006 Weight (g) 1485 1775 2110 2380 39.5 3010 4620 6530 Age (weeks pea) 33.7 34.7 35.7 37.0 40.1 48.1 57.0 Female DHA 9709-0001 Weight (g) 1250 1490 1755 1970 2250 2520 33.8 3500 Age (weeks pea) 29.6 31.0 32.0 33.0 34.0 35.0 40.1 Female DHA 9709-0003 Weight (g) 1540 1725 2015 2155 30.5 2580 4080 5420 Age (weeks pea) 34.4 35.4 36.4 37.4 40.3 47.7 57.1 Four subjects had more the 9 weights used in growth rate calculation. A complete listing appears on the last page. Appendix 1 Listing of Weights Included in the Statistical Analyses Growth Rate Gender Regimen Subject Variable Wgt1 Wgt2 Wgt3 Wgt4 Wgt5 Wgt6 Wgt7 Wgt8 Wgt9 g/day Wgt_40 Wgt_48 Wgt_57 Female DHA 9712-0001 Weight (g) 987.0 1120 1270 1470 1685 24.9 2940 3980 5250 Age (weeks pea) 30.0 31.0 32.0 33.0 34.0 40.1 48.1 57.1 Female DHA 9712-0002 Weight (g) 1060 1230 1430 26.4 Age (weeks pea) 32.7 33.7 34.7 Female DHA 9712-0007 Weight (g) 1082 1230 1440 1650 27.3 2425 4250 5340 Age (weeks pea) 32.7 33.7 34.7 35.7 39.7 47.9 56.9 Female DHA 9743-0001 Weight (g) 1000 1170 1470 1800 1930 33.5 4140 5400 Age (weeks pea) 32.1 33.1 34.4 35.7 36.1 48.3 57.3 Female DHA 9743-0002 Weight (g) 1380 1570 1845 1975 29.7 4540 5160 Age (weeks pea) 32.1 33.3 34.1 35.1 48.4 57.4 Female DHA+ARA 9698-0001 Weight (g) 1550 1690 2000 2380 37.1 3530 5348 6582 Age (weeks pea) 31.6 32.6 33.6 34.9 40.0 47.7 56.7 FemaIe DHA+ARA 9698-0002 Weight (g) 1580 1870 2130 2260 31.8 3241 Age (weeks pea) 32.6 33.7 34.6 35.7 40.7 Female DHA+ARA 9699-0004 Weight (g) 985.0 1122 1283 1536 1788 28.9 3177 5107 6979 Age (weeks pea) 31.0 32.0 33.0 34.0 35.0 41.3 48.3 57.3 Female DHA+ARA 9699-0005 Weight (g) 1330 1542 1688 2000 2330 35.1 4029 6752 8341 Age (weeks pea) 31.9 32.9 33.9 34.9 35.9 40.0 48.0 57.0 Female DHA+ARA 9700-0002 Weight (g) 1315 1525 1885 2035 2220 2480 31.9 3340 4930 6420 Age (weeks pea) 30.3 31.3 32.3 33.3 34.1 35.6 40.3 48.1 57.1 Female DHA+ARA 9701-0002 Weight (g) 1398 1609 1887 2210 2420 37.8 2930 5115 6525 Age (weeks pea) 33.4 34.4 35.4 36.4 37.4 39.4 48.4 56.4 Female DHA+ARA 9701-0006 Weight (g) 1720 1859 2113 2456 2728 38.3 3600 5045 6270 Age (weeks pea) 32.3 33.3 34.3 35.3 36.1 40.3 48.0 57.3 Female DHA+ARA 9701-0007 Weight (g) 1469 1427 1590 1982 2227 29.8 2680 4935 6955 Age (weeks pea) 33.7 34.9 35.7 36.7 37.7 39.9 47.9 56.9 * Four subjects had more the 9 weights used in growth rate calculation. A complete listing appears on the last page. Appendix 1 Listing of Weights Included in the Statistical Analyses Growth Rate Gender Regimen Subject Variable Wgt1 Wgt2 Wgt3 Wgt4 Wgt5 Wgt6 Wgt7 Wgt8 Wgt9 g/day Wgt_40 Ugt .8 Wgt_5 ' ι Female DHA+ARA 9701-0010 Weight (g) 1488 1703 1978 2234 2433 2759 34.6 3500 5545 Age (weeks pea) 32.3 33.4 34.4 35.3 36.1 37.7 41.1 48.4 Female DHA+ARA 9701-0013 Weight (g) 1841 2019 35.6 4545 5550 Age (weeks pea) 33.0 33.7 48.7 57.4 Female DHA+ARA 9702-0003 Weight (g) 1293 1488 1820 2155 2400 39.9 4190 6220 7500 Age (weeks pea) 30.1 31.1 32.1 33.4 34.1 40.0 48.4 56.9 Femate DHA+ARA 9702-0005 Weight (g) 1895 2060 2300 2525 2710 29.9 3025 4300 5340 Age (weeks pea) 34.0 35.0 36.0 37.0 38.0 40.0 47.4 56.4 Female DHA+ARA 9702-0009 Weight (g) 1725 2000 2230 2595 2655 40.9 2905 4680 6410 Age (weeks pea) 34.0 35.0 36.0 37.0 37.3 39.9 48.3 57.6 FemaI e DHA+ARA 9703-0001 Weight (g) 1145 1255 1450 1680 1955 28.9 3030 4250 5420 Age (weeks pea) 31.3 32.1 33.1 34.3 35.3 41.0 48.1 57.3 Female DHA+ARA 9703-0006 Weight (g) 1865 2200 2560 2880 49.1 3600 5400 6650 Age (weeks pea) 34.0 35.0 35.9 37.0 40.0 48.1 56.7 FemaI e DHA+ARA 9703-0007 Weight (g) 1390 1495 1620 1880 2030 2240 27.4 2850 4190 5B50 Age (weeks pea) 32.0 33.1 34.0 35.0 35.7 36.6 40.0 47.9 56.7 emale DHA+ARA 9704-0002 Weight (g) 960.0 1090 1200 1370 1570 1780 2070 26.7 3110 5150 6800 Age (weeks pea) 29.0 30.0 30.9 31.9 32.9 33.9 34.9 40.0 48.0 57.3 Female DHA+ARA 9704-0003 Weight (g) 1690 1840 30.0 4000 5400 6640 Age (weeks pea) 32.7 33.4 40.0 48.0 57.0 FemaI e DHA+ARA 9705-0003 Weight (g) 1760 2260 2500 2920 49.8 3376 5107 6894 Age (weeks pea) 34.4 35.7 36.6 37.7 39.9 48.4 56.9 Female DHA+ARA 9705-0005* Weight (g) 1075 1120 1185 1280 1310 1310 1265 1350 1380 22.1 2600 4000 5050 Age (weeks pea) 31.1 31.4 31.7 32.1 32.4 32.7 33.0 33.3 33.4 40.4 48.0 57.0 Female DHA+ARA 9706-0001 Weight (g) 1290 1515 1685 2060 34.5 4100 6550 7655 Age (weeks pea) 31.7 32.9 33.7 34.9 40.1 48.6 56.7 * Four subjects had more the 9 weights used in growth rate calculation. A complete listing appears on the last page. Appendi 1 Listing of Weights Included in the Statistical Analyses Growth Rate Gender Regimen Subject Variable Wgt1 Wgt2 Wgt3 Wgt4 Wgt5 Wgt6 Wgt7 Wgt8 Wgt9 g/day Wgt_40 Wgt_48 Wgt Female DHA+ARA 9706-0002 Weight (g) 1395 1710 1884 2275 34.8 2845 4645 5550 Age (weeks pea) 31.9 33.0 33.9 35.4 40.3 48.9 57.3 Female DHA+ARA 9706-0004 Weight (g) 1550 1705 2050 36.1 2645 4225 4935 Age (weeks pea) 36.7 37.6 38.7 41.7 49.7 58.0 Female DHA+ARA 9706-0007 Weight (g) 1235 1490 1820 1930 34.3 2505 Age (weeks pea) 33.4 34.6 35.7 36.4 40.3 Female DHA+ARA 9706-0011 Weight (g) 1900 2105 41.0 3430 5175 6140 Age (weeks pea) 34.3 35.0 40.0 48.4 56.7 Female DHA+ARA 9706-0015 Weight (g) 1670 1975 2210 41.6 3005 4465 5810 Age (weeks pea) 34.6 35.6 36.4 40.9 48.4 57.6 Female DHA+ARA 9706-0017 Weight (g) 1465 1700 1895 2170 33.4 Age (weeks pea) 32.3 33.4 34.3 35.3 Female DHA+ARA 9707-0002 Weight (g) 1775 2240 2385 2610 33.2 Age (weeks pea) 34.3 36.0 36.9 37.9 Female DHA+ARA 9708-0002 Weight (g) 1535 1700 1980 2200 32.5 2724 4645 6315 Age (weeks pea) 33.0 34.0 35.0 36.0 38.1 47.6 55.4 Female DHA+ARA 9708-0005 Weight (g) 1125 1345 1610 1980 40.4 3121 5855 7875 Age (weeks pea) 32.4 33.4 34.4 35.4 39.4 47.4 57.4 Female DHA+ARA 9708-0007 Weight (g) 1200 1440 1680 1975 36.6 Age (weeks pea) 31.3 32.3 33.3 34.3 Female DHA+ARA 9709-0004 Weight (g) 1350 1560 1885 2250 2475 37.0 3295 5250 6685 Age (weeks pea) 31.9 33.3 34.6 35.6 36.3 39.7 48.4 56.7 Female DHA+ARA 9712-0003 Weight (g) 1283 1410 1590 1850 2010 27.1 2580 4130 5640 Age (weeks pea) 32.0 33.0 34.0 35.0 36.0 40.0 48.2 57.5 Female DHA+ARA 9712-0004 Weight (g) 1575 1780 1890 2080 2530 29.7 3220 4920 6600 Age (weeks pea) 33.0 34.0 34.6 35.6 37.6 40.3 48.1 57.1 * Four subjects had more the 9 weights used in growth rate calculation. A complete listing appears on the last page. Appendix 1 Listing of Weights Included in the Statistical Analyses Growth Rate Gender Regimen Subject Variable Wgt1 Wgt2 Wgt3 Wgt4 Wgt5 Wgt6 Wgt7 Wgt8 g/day Ugt_40 Wgt_48 Wgt_57 Female DHA+ARA 9712-0008 Weight (g) 1590 1780 1990 2475 37.2 2960 4470 5760 Age (weeks pea) 34.0 35.0 35.8 37.4 40.1 48.1 57.1 Female DHA+ARA 9746-0002 Weight (g) 1249 1429 1597 1814 2110 30.1 2680 4010 5362 Age (weeks pea) 32.7 33.7 34.7 35.7 36.7 39.9 46.9 56.9 Female HH 9698-0501 3546 4880 40.0 48.3 Female HH 9698-0502 3518 5972 40.0 47.9 Female HM 9698-0503 3390 4213 5319 40.0 48.3 57.1 FemaI e HM 9698-0504 3383 5234 6667 40.0 48.7 57.9 Female HH 9698-0505 3646 4638 5653 40.0 48.3 57.0 Female HH 9699-0601 2582 4766 5731 40.0 49.0 57.0 Female HH 9699-0602 4284 4823 5986 40.0 48.0 57.0 Female HM 9699-0603 3716 4482 5674 40.0 47.7 56.7 Female HH 9699-0604 3660 4738 6355 40.0 48.0 57.0 Female HH 9699-0605 3433 5617 7603 40.0 48.4 57.6 Female HH 9701-0501 3884 5630 6450 40.0 47.7 57.7 * Four subjects had more the 9 weights used in growth rate calculation. A complete listing appears on the last page. Appendix 1 Listing of Weights Included in the Statistical Analyses Growth Rate Gender Regimen Subject Variable Wgt1 Wgt2 Wgt3 Wgt4 Wgt5 Wgt6 Wgt7 Ugtβ Wgt9 g/day Wgt_40 Wgt_48 Wgt_5 Female HH 9701-0502 3858 5420 6700 40.0 48.6 57.6 Female HH 9701-0503 3430 4265 5085 40.0 47.4 57.4 Female HH 9701-0504 3317 5020 6230 40.0 48.1 57.1 Female HH 9702-0501 3302 5540 6630 40.0 47.7 56.7 Female HM 9702-0502 2658 5310 6800 40.0 47.4 57.1 Female HH 9702-0503 2895 3430 4530 40.0 47.7 57.4 1 ^ Female HM 9702-0504 3401 5390 6270 1 40.0 48.0 57.4 Female HH 9702-0505 3141 4210 5320 40.0 47.9 57.0 Female HH 9702-0506 3762 6040 7600 40.0 48.9 57.7 Female HH 9702-0507 2718 4050 4940 40.0 48.9 57.4 Female HH 9702-0508 2927 4240 5860 40.0 47.4 57.0 Female HH 9703-0501 4085 5260 6360 40.0 48.1 57.1 Female HH 9703-0505 3390 5760 7670 40.0 48.3 57.3 Four subjects had more the 9 weights used in growth rate calculation. A complete listing appears on the last page. Appendix 1 Listing of Weights Included in the Statistical Analyses Growth Rate Gender Regimen Subject Variable Wgt1 Wgt2 Wgt3 Wgt4 Wgt5 Wgt6 Wgt7 Wgt8 Wgt9 g/day Wgt_40 Wgt_48 Wgt_57 Female HH 9703-0506 3405 6170 7490 40.0 47.9 56.9 Female HH 9703-0507 3085 5090 6550 40.0 48.0 56.3 Female HH 9704-0501 3194 4700 5880 40.0 48.1 57.4 Female HH 9705-0501 3120 4500 5702 40.0 48.1 57.1 Female HM 9705-0502 4080 6327 7348 40.0 48.3 57.3 Female HH 9706-0501 3396 5000 6645 40.0 48.3 58.1 Female HH 9706-0502 3041 4315 5525 40.0 47.7 57.6 Female HH 9707-0501 4653 5515 6770 40.0 47.9 56.6 Female HH 9707-0502 3419 5500 7080 40.0 48.0 57.1 Female HM 9707-0503 3773 5785 7675 40.0 47.9 56.9 Female HM 9707-0505 3716 40.0 Female HM 9708-0501 3688 5440 6890 40.0 48.1 57.6 Female HM 9708-0502 3454 5192 5950 40.0 48.1 57.4 * Four subjects had more the 9 weights used in growth rate calculation. A complete listing appears on the last page. Appendix 1 Listing of Weights Included in the Statistical Analyses Growth Rate Gender Regimen Subject Variable Wgt1 Wgt2 Wgt3 Wgt4 Wgt5 Ugt6 Wgt7 Wgt β Ugt9 g/day Wgt 40 Wgt_48 Wgt_57 Female HH 9708-0503 22997777 55_,_1166_55. 77-,00.44.00 40.0 48.1 57.4_, Female HH 9708-0504 3864 5660 6705 40.0 48.4 57.4 Female HH 9708-0505 3831 5800 7435 40.0 47.7 57.6 Female HH 9709-0501 3550 40.0 Female HM 9709-0502 3715 5205 6100 40.0 48.0 56.9 Female HH 9709-0503 3195 1 40.0 --4 Female HH 9709-0504 3190 4590 40.0 48.3 Female HM 9709-0506 3505 4500 5910 40.0 48.0 57.1 * Four subjects had more the 9 weights used in growth rate calculation. A complete listing appears on the last page. Appendix 1 Listing of Weights Included in the Statistical Analyses Growth Rate Gender Regimen SUBJECT Variable Wgtl Wgt2 Wgt3 Wgt4 Wgt5 Wgt6 Wgt7 Wgtβ Wgt9 WgtIO Wgt11 Wgt12 Wgt13 Wgt14 Wgt15 Wgt16 Wgt17 Wgtlβ g/day Hale Control 9712-0301 Weight (g) 1245 1221 1245 1291 1294 1330 1369 1402 1433 1448 1465 26.1 Age (weeks pea) 31.6 31.7 31.9 32.0 32.1 32.3 32.4 32.6 32.7 32.9 33.0 Hale DHA 9707-0307 Weight (g) 1649 1675 1699 1732 177B 1811 1858 1882 1938 1994 2030 2075 39.6 Age (weeks pea) 32.4 32.6 32.7 32.9 33.0 33.1 33.3 33.4 33.6 33.7 33.9 34.0 Female Control 9698-0003 Weight (g) 1020 1050 1070 1080 1080 1060 1080 1070 5.6 Age (weeks pea) 31.1 31.3 31.4 31.6 31.7 31.9 32.0 32.1 Female DHA+ARA 9705-0005 Weight (g) 1075 1120 1185 1280 1310 1310 1265 1350 1380 1440 1450 1510 1515 1565 1585 1640 1680 1670 22.1 Age (weeks pea) 31.1 31.4 31.7 32.1 32.4 32.7 33.0 33.3 33.4 33.7 33.9 34.0 34.1 34.3 34.4 34.6 34.7 34.9

Claims: What is claimed is: 1. A method for enhancing the growth of preterm infants comprising administering to said infants a growth enhancing amount of DHA and ARA. 2. The method of Claim 1 wherem DHA and ARA are supplemented into infant formula. 3. The method of Claim 1 wherein the ratio of ARA:DHA is 1:2 to 5:1. 4. The method of Claim 1 wherein the ratio of ARA:DHA is 1.1 to 3 : 1. 5. The method of Claim 1 wherein the ratio of ARA:DHA is about 2:1. 6. The method of Claim 2 wherein the infant formula comprises DHA in an amount of about 2 mg/100 kcal to about 50 mg/100 kcal and ARA in an amount of about 4 mg/100 kcal to about 100 mg/100 kcal. 7. The method of Claim 2 wherein the infant formula comprises DHA in an amount of about 5 mg/100 kcal to about 33 mg/100 kcal and ARA in an amount of about 10 mg/100 kcal to about 67 mg/100 kcal. 8. The method of Claim 2 wherein the infant formula comprises DHA in an amount of about 15 mg/100 kcal to about 20 mg/100 kcal and ARA in an amount of about 30 mg/100 kcal to about 40 mg/100 kcal. 9. The method of Claim 1 wherein the amount of time to achieve growth equivalent to normal terms breast fed infants is less than 9 months corrected age. 10. The method of Claim 1 wherein the amount of time to achieve growth equivalent to normal terms breast fed infants is less than 6 months corrected age. 11. The method of Claim 1 wherein the amount of time to achieve growth equivalent to normal terms breast fed infants is less than 4 months corrected age. 12. The method of Claim 1 wherein the amount of time to achieve growth equivalent to normal terms breast fed infants is less than 2 months corrected age. 13. The method of Claim 1 wherein the amount of time to achieve growth equivalent to normal terms breast fed infants is no greater than term corrected age.

Inventors: HANSEN JAMES W, MERKEL KIMBERLY L, SCHADE DEBORAH A, HANSEN, JAMES, W., MERKEL, KIMBERLY, L., SCHADE, DEBORAH, A.
Applicants: HANSEN JAMES W, MERKEL KIMBERLY L, SCHADE DEBORAH A, SQUIBB BRISTOL MYERS CO, BRISTOL-MYERS SQUIBB COMPANY, HANSEN, JAMES, W., MERKEL, KIMBERLY, L., SCHADE, DEBORAH, A.
Application year: 1998
Main classification: A61K31
IPC codes: A61K31